Belgian Week of Gastroenterology

0 9

Ostend, February 9 - 11, 2012

T h u r s d a y

Belgian Week of Gastroenterology XXIVth

edition

F r i d a y 1 0 S a t u r d a y

www.belgianweek.be or www.bwge.be

1 1

T h u r s d a y

Welcome address Dear Colleagues, It is my pleasure to invite you to our 24th Belgian Week of Gastroenterology taking place from February 9 till February 11, 2012 in the beautiful city of Ostend.

9

This year we have chosen Ostend as conference location to give everyone the opportunity to enjoy the North Sea during winter time again. The Thermae Palace, completely hired for the BWG, will host the congress. There is space for the exhibition and the posters and walking lunch every day. This year we received around 180 abstracts for all the different research groups and the best ones will be presented at the plenary session on Friday afternoon. Of course I would like to invite you to come to our Dinner & Party on Friday February10th held in the “Koninklijke Gaanderijen”, next to the Thermae Palace, within walking distance. A nice dinner and music for a splendid evening and night !

F r i d a y

On Saturday we have the Seven Societies Postgraduate Course organised by the Belgian Association for the Study of the Liver (BASL) and the title is: “Management of complications of cirrhosis”. An impressive Faculty composed of experts known internationally is enhancing our program ! Partners are also welcome and Ostend is a fantastic city with lots of facilities and nice shops and Brugge is only 30 km away for a wonderful walk in the old and renovated city.

1 0

I would like to thank all scientific committees and biomedical partners for their support in organising this Belgian Week of Gastroenterology 2012. .

Isabelle Colle Scientific Coordinator

S a t u r d a y

All abstracts of lectures will be published in Acta Gastroenterologica Belgica. Acta Gastroenterologica is accessible on internet : www.acta-gastroenterologica.be Editor-in-Chief: Peter STARKEL Deputy Editor: Daniel URBAIN

1 1

X x I V t h • B e l g i a n W e e k o f G a s t r o e n t e r o l o g y • o s t e n d , F e b r u a r y 9 - 11, 2 012

3

T h u r s d a y

WelcomE address

3

FRIDAY FEBRUARY 10 :

STEERING COMMITTEE

6

BGDO/RADIOLOGY/PATHOLOGY/NUCLEAR MEDICINE 32

INVITED LECTURES

8

BGDO

SATELLITE SYMPOSIA

12

1 1

34

PAEDIATRICS : BeSPGHAN

36

BIRD

40

BASL / BLIC

14

PLENARY SESSION

42

BASL / BLIC poster session

18

POSTER SESSION

44

OG – FWO

21

FRIDAY NIGHT PARTY

24

BELGIAN PANCREATIC CLUB

48

PROGRAM OVERVIEW

26

SATURDAY FEBRUARY 11 :

BSGIE

28

BIRD

29

NUTRITION

30

ACCESS

52

BWG 2012 PARTNERS

56

7 SOCIETIES POSTGRADUATE COURSE :

50 S a t u r d a y 1 1

SA T URDAY

RADIOLOGY/PATHOLOGY

1 0

F RIDAY

THURSDAY FEBRUARY 9 :

33

F r i d a y

1 0

9

T h u r s d a y

9

INDEX

4



5

9

steering committee

T h u r s d a y

Scientific Coordinator Isabelle COLLE

G. VAN ASSCHE, M. PEETERS (VVGE, Vlaamse Vereniging voor Gastro-Enterologie)

J.L. VAN LAETHEM, J. DEFLANDRE (SRBGE, Société Royale BeIge de Gastro-Entérologie)

P. DEPREZ, P. VAN DER SPEK

Scientific Secretaries of the Seven Societies Symposium Belgian Association for the study of the Liver (BASL)

Gélules Harde capsules

H. REYNAERT, P. STÄRKEL, I. COLLE, J. PIRENNE, H. VAN VLIERBERGHE

(BSGIE, Belgian Society of Gastrointestinal Endoscopy)

1 0

A. de Roover, J. Lerut, J. M. Collard (upper G.I section), P. Pattyn (colo-rectal section), R. Troisi (HBP section) (RBSS, Royal Belgian Society of Surgery)

F RIDAY

B. OP DE BEECK, E. DANSE (SRBR-KBVR, Royal Belgian Society of Radiology, Digestive Radiology and Abdominal Imaging)

H. REYNAERT, P. Stärkel

Glyceryltrinitraat rectale zalf

(BASL, Belgian Association for the Study of the Liver)

E. VANCUTSEM, M. PEETERS (BGDO, Belgian Group of Digestive Oncology)

I. DEPOORTERE, G. BOECKXSTAENS

S. VERMEIRE, D. FRANCHIMONT

(OG-FWO, Gastro-intestinal regulatory mechanisms)

(Belgian IBD Research Group)

A. HOORENS, A. JOURET-MOURIN

M. DELHAYE

(Gastro-Intestinal Pathology Club)

(BPC, Belgian Pancreatic Club)

G. VEEREMAN, I. HOFFMAN, Y. VANDENPLAS

V. LAMY, F. MANA

(BeSPGHAN, Belgian Society for Paediatric Gastroenterology, Hepatology and Nutrition)

D. URBAIN

A. VAN GOSSUM

J. PIRENNE, H. VAN VLIERBERGHE

(SBNC, Société Belge de Nutrition Clinique)

(BLIC, Belgian Liver Intestine Committee)

D. YSEBAERT

M. LONNEUX, C. VAN DE WIELE, P. FLAMEN, B. LAMBERT

(VVKVM, Vlaamse Vereniging voor Klinische Voeding en Metabolisme) 6

(BHPSG, Belgian Helicobacter Pylori Study Group) (Belgian Small Bowel Group)

(Nuclear Medicine)


10.394 – 12/08/6

SA T URDAY

1 1

Research Groups

Trinitrate de glycéryle pommade rectale

ENT 10 442/12/08/15

Seven Societies

T h u r s d a y

9

I NVITE D LE CTU R E s THURSDAY FEBRUARY

BASL / BLIC : Room Astrid 12h30: Liver transplantation in Belgium seen from the Eurotransplant view point: implications of MELD in Belgium. J. BLOCK (Eurotransplant, Leiden, The Netherlands) OG-FWO : Room Fabiola 09h00: The Eosinophil and the Gastrointestinal Tract – A friend or a Foe ? A. STRAUMANN (Olten, Switzerland) 10h55: Analysis of the IBD Kinome : Potential Applications. M. PEPPELENBOSCH (Rotterdam, The Netherlands)

11h15: Laparoscopic pancreatic resections. C. HUBERT (UCL St Luc, Brussels)

FRIDAY FEBRUARI 10

BGDO/ Radiology/ Pathology Club/ Nuclear Medicine : ROOM ASTRID 08h35: Radiology imaging in NET: pitfall and challenges. L. ANNET (UCL St Luc, Brussels) 09h00: The diagnostic and therapeutic role of nuclear medicine in NET. C. DE ROOSE (KULeuven) 09h25: Medical treatment of NET. A. HENDLISZ (Bordet, Brussels) 09h50: Pathologic classification of NET. G. RINDI (Rome, Italy) 11h30: “Colorectal cancer.” G. Demoulin / ULg

F r i d a y

Belgian Pancreatic Club : Room Leopold III 09h00: Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) in pancreatic diseases. C. MATOS (Erasme, Brussels)

I NVITE D LE CTU R E s

11h50: “HepatoBiliopancreatic cancer.” C. Verslype /KULeuven.

BASL / BLIC : Room Astrid M. Hautekeete Lecture. 16h00: What you should know about pediatric hepatology. G. MIELI-VERGANI (London, U.K.)

12h10: “ Oesophagastric cancer.”

OG-FWO : Room Fabiola 14h00: Ratting out IBS R. VAN DEN WIJNGAARD (Amsterdam, The Netherlands)

BeSPGHAN/HP : ROOM BAUDOUIN 08h30: I BD and probiotics. G. VEEREMAN (UZ Brussels)

BSGIE/ SMALL BOWEL GROUP : Room Leopold III 14h00: Acute pancreatitis: diagnostic endoscopy. P. DEPREZ (UCL St Luc, Brussels)

09h10: Obesity, type 2 diabetes and gut microbiota. P.D. CANI (UCL St Luc, Brussels)

15h00: Acute pancreatitis: endoscopic therapy. O. LE MOINE (Erasme, Brussels)

09h35: Asthma and the intestinal microbiota. C. VAEL (KLINA, Antwerp)

16h40: Acute pancreatitis: endoscopic therapy of acute pseudocyst and necrosis. M. BARTHET (Marseille, France)

10h40: Composition and functions of the human gut microbiota: novel insights. F. GUARNER (Barcelona, Spain)

BIRD IMMUNOLOGY : Room Baudouin 14h00: The microbial flora: A review on microbiology and techniques. J. RAES (VIB Brussels)

11h25: “Maastricht 4 - new or old treatments for Belgium.” A. Burette (CHIREC/sites de la Basilique & E. Cavell, Brussels)

15h15: Bacterial handling and Autophagy in health and Disease. K. CADWELL (New York, USA)

11h45: H. pylori: a fairytale. S. CADRANEL (ULB HUDERF, Brussels)

K. Geboes /UZGent

1 0

16h45: UC genetics and pathogenesis: How different is UC from CD ? S. DANESE (Milan, Italy) 8



9


1 0

SATURDAY FEBRUARY 11

BIRD/ IBD: ROOM FABIOLA 8h30: Personalized medicine: optimizing anti-TNF therapies (trough levels) . F. Baert (HH Roeselaere)

Seven Societies Postgraduate Course (BASL) : ROOMS FABIOLA & BAUDOUIN 09h00: Prognostic factors in liver biopsy for HCC. J. ZUCMAN ROSSI (Paris, France)

9h45: Colon cancer in IBD: Is the risk still significant today? D. Franchimont (ULB Erasme, Brussels)

09h25: Staging and local treatment of HCC. B. Op de Beeck (UZAntwerpen)

11h30: New scores in IBD: the disability index and Lemann score. L. PEYRIN-BIROULET (Nancy, France)

09h50: Indications for transplantations and management of HCC while on waiting list. J.F. DUFOUR (Bern, Switzerland)

FRIDAY FEBRUARY 10

10h15: Medical treatment of advanced HCC. C. VERSLYPE (KULeuven)

BWG PLENARY SESSION : ROOMS FABIOLA & BAUDOUIN 15h12: G WAS for the gastroenterologist : clinical implications S. VERMEIRE (KULeuven)

F RIDAY


PATHOLOGY: ROOM LEOPOLD III 14h00: Lymphatics in IBD, friend or foe? J.F. RAHIER (UCL Mt Godinne) 15h45: Correct histopathological staging of colorectal cancer : a challenging issue P. DEMETTER (ULB Erasme, Brussels)

11h00: P athophysiology of portal hypertension. H. REYNAERT (UZBrussel) 11h20: Management of acute variceal bleeding and GAVE. O. LE MOINE (ULB Erasme, Brussels) 11h40: P rimary and Secondary prophylaxis of variceal bleeding. P. STÄRKEL (UCL St Luc, Brussels) 12h00: Management of children with GI haemorrhage due to portal hypertension. X. STEPHENNE (UCL St Luc, Brussels) 14h15: B ROHEE LECTURE: Update in treatment of achalasia. G. BOECKXSTAENS (KULeuven) 14h30: Ascites and hyponatremia. S. FRANCQUE (UZA) 14h50: Renal dysfunction in cirrhosis. M. WISSING (UZBrussel) S a t u r d a y

15h10: Spontaneous bacterial peritonitis and other infections. T. GUSTOT (ULB, Brussels) 15h30: H epatopulmonary syndrome and portopulmonary hypertension. H. VAN VLIERBERGHE (UZGent) 15h50: Coagulation disorders in cirrhosis (hypo and hyper). J. SCHOUTEN (Rotterdam, the Netherlands) 16h10: Indications for liver transplantation in end stage liver disease. J. DELWAIDE (ULg)

1 1

10



11

9 T h u r s d a y 1 0 F RIDAY

SATELLITE SYMPOSIA T h u r s d ay

feb r u a r y

09

Speakers : C. Matos (Erasme, Brussels) / S. Segaert (KULeuven)

Room Horizon 13h15-14h00 MSD «Implementation of a new DAA in clinical practice for genotype 1 chronic hepatitis C patients». Speakers: M. Cornberg (Hannover, Germany) Room Horizon 17h30-18h15 GILEAD «Chalenging Patient Decisions in Chronic HBV» Speakers: S. Mauss (Dusseldorf, Germany) F r i d ay

feb r u a r y

10

Room FABIOLA 07h45-08h30 CHIESI «Steroids in IBD: really the Devil ?».

Speakers: D. Franchimont (ULB Erasme) / S. Danese (Milan, Italy) / M. Devos (UZGent) / S. Vermeire (KULeuven) / E. Louis (Ulg)

Speakers: L. Peyrin-Biroulet (Nancy, France) / E. Louis (CHU Liège) / S. Vermeire (KULeuven)

1 1

E E ff fica fica cc yy & & Sec Sec u u rity rity combin combin ed ed

Room Horizon 12h30-13h15 BAYER «HCC: Fine tuning the diagnosis, optimizing the treatment».

Room HORIZON 12h30-13h15 ABBOTT «Leading Change in CD».

Room HORIZON 13h15-14h00 PFIZER «Improving patients outcomes in pancreatic neuroendocrine tumours (pNET)». Speakers: I. Borbath (UCL St Luc) / C. Verslype (KULeuven)

S a tU r d a y

feb r u a r y

11

Room LEOPOLD III 13h30-14h15 THERASPHERE – NORDION «Radioembolization using Yttrium-90 glass microspheres in HCC and liver metastases». Speakers: S. Bhoori (Milan, Italy) / P. Hilgard (Mulheim, Germany)

12


Treatment of choice for Bleeding Oesophageal Varices DENOMINATION – FORME PHARMACEUTIQUE – COMPOSITION : SOMATOSTATINEEUMEDICA 250 μg poudre et solvant pour solution pour injection (contient 250 μg de Somatostatine base sous forme somatostatine acétate hydraté) - SOMATOSTATINE-EUMEDICA 3 mg poudre et solvant pour solution pour perfusion (contient 3 mg de Somatostatine base sous forme de somatostatine acétate hydraté) - SOMATOSTATINE-EUMEDICA 6 mg poudre et solvant pour solution pour perfusion (contient 6 mg de Somatostatine base sous forme de somatostatine acétate hydraté). INDICATIONS : - Traitement des fistules intestinales et pancréatiques. - Traitement symptomatique des hypersécrétions occasionnées par des tumeurs endocrines du tractus gastro-intestinal. - Traitement de l’hémorragie œsophagienne aiguë lorsque la sclérothérapie endoscopique n’est pas applicable, en raison de l’intensité de l’hémorragie. L’administration de la Somatostatine n’est pas recommandée plus de 48 heures. POSOLOGIE ET MODE D’ADMINISTRATION : Voie intraveineuse. La dose initiale sera de 3,5 µg par kg environ (soit une ampoule de 250 µg pour une personne de 75 kg), diluée extemporanément dans l’ampoule de solvant isotonique, administrée en I.V. en bolus lent (plus d’une minute). Elle sera immédiatement suivie d’une perfusion I.V. continue de 3,5 µg par kg et par heure (soit une ampoule de 3 mg par 12 heures ou une ampoule de 6 mg par 24 heures) pendant plusieurs jours (48 heures minimum et 120 heures maximum). Chez les patients souffrant d’insuffisance rénale sévère (clairance à la créatinine ≤ 30 ml/min), la posologie sera réduite à 1,75 µg par kg et par heure pour une perfusion IV continue et à 1,75 µg par kg en bolus. Etant donné la courte demi-vie de 1 à 2 minutes, une perfusion intraveineuse continue est indispensable. La SOMATOSTATINE EUMEDICA sera utilisée de préférence dans une salle de soins intensifs. CONTRE-INDICATIONS : Hypersensibilité à la somatostatine ou à des analogues de la somatostatine. EFFETS INDESIRABLES : Les effets indésirables suivants ont été rapportés spontanément: troubles cardiaques : bloc auriculo-ventriculaire, bradycardie, - troubles gastrointestinaux : douleur abdominale, diarrhée, nausées, - troubles du métabolisme et de la nutrition : hyperglycémie, hypoglycémie, - troubles vasculaires : hypertension, hypotension, bouffées de chaleur. Des bouffées de chaleur, des nausées, des douleurs abdominales, de la diarrhée observées en cas d’injection rapide, peuvent être évitées par une injection lente. L’interruption abrupte d’une perfusion continue peut provoquer un effet rebound de la pathologie traitée particulièrement lors du traitement de fistules. TITULAIRE DE L’AUTORISATION DE MISE SUR LE MARCHE : EUMEDICA SA - Avenue Winston Churchill 67 - 1180 Bruxelles - Belgique. AMM N°: SOMATOSTATINE-EUMEDICA 250 μg : BE 133375 - SOMATOSTATINE-EUMEDICA 3 mg : BE 133384. SOMATOSTATINE-EUMEDICA 6 mg : BE 152975. Sur prescription médicale. Pour une information complète, veuillez consulter le résumé des caractéristiques du produit, disponible à la demande.

Operation site:

Chemin de Nauwelette 1 • 7170 MANAGE  064 27 17 00 •  064 27 17 99 • [email protected]

NAAM – FARMACEUTISCHE VORM – SAMENSTELLING : SOMATOSTATINE-EUMEDICA 250 μg poeder en oplosmiddel voor oplossing voor injectie (bevat 250 μg Somatostatinebase onder vorm van somatostatine acetaathydraat) - SOMATOSTATINEEUMEDICA 3 mg poeder en oplosmiddel voor oplossing voor infusie (bevat 3 mg Somatostatinebase onder vorm van somatostatine acetaathydraat) - SOMATOSTATINE-EUMEDICA 6 mg poeder en oplosmiddel voor oplossing voor infusie (bevat 6 mg Somatostatinebase onder vorm van somatostatine acetaathydraat). INDICATIES: Behandeling van darm- en pancreasfistels. - Symptomatische behandeling van hypersecretie door endocriene tumoren van het spijsverteringsstelsel. - Behandeling van acute slokdarmbloeding wanneer endoscopische sclerotherapie niet kan worden toegepast wegens de intensiteit van de bloeding. Het is niet aanbevolen om somatostatine langer dan 48 uren toe te dienen. DOSERING EN WIJZE VAN TOEDIENING : Intraveneus. De initiële dosis bedraagt ongeveer 3,5 µg per kg (hetzij één ampul van 250 µg voor een persoon van 75 kg), extemporaneus verdund met de ampul isotonisch oplosmiddel, toegediend als trage I.V. bolus (meer dan één minuut). Deze moet onmiddellijk gevolgd worden door een continue I.V. infusie van 3,5 µg per kg en per uur (hetzij één ampul van 3 mg per 12 uren of één ampul van 6 mg per 24 uren) gedurende meerdere dagen (minimum 48 uren en maximum 120 uren). Bij patiënten met ernstige nierinsufficiëntie (creatinineklaring ≤ 30 ml/min) moet de dosering worden verminderd tot 1,75 µg per kg en per uur voor een continue, I.V. infusie en tot 1,75 µg per kg voor de bolus. Omwille van de korte halfwaardetijd van 1 à 2 minuten is continue I.V. infusie noodzakelijk. SOMATOSTATINE EUMEDICA zal bij voorkeur gebruikt worden in een afdeling voor intensieve zorgen. CONTRAINDICATIES : Overgevoeligheid voor somatostatine of voor somatostatineanalogen. BIJWERKINGEN : De volgende bijwerkingen werden spontaan gemeld : - Hartaandoeningen : atrioventriculaire blok, bradycardie, - Maagdarmstelselaandoeningen: buikpijn, diarree, nausea, - Voedings- en stofwisselingsstoornissen: hyperglykemie, hypoglykemie, - Bloedvataandoeningen : hypertensie, hypotensie, warmteopwellingen. Warmteopwellingen, nausea, buikpijn, diarree die worden waargenomen bij snelle injectie, kunnen voorkomen worden door een trage injectie. Plotse onderbreking van een continue infusie kan een rebound effect van de behandelde aandoening veroorzaken, in het bijzonder bij behandeling van fistels. HOUDER VAN DE VERGUNNING VOOR HET IN DE HANDEL BRENGEN : Eumedica NV - Winston Churchilllaan 67 - B-1180 Brussel - Belgie. VHB Nr : SOMATOSTATINE-EUMEDICA 250 μg : BE133375 - SOMATOSTATINE-EUMEDICA 3 mg : BE133384. SOMATOSTATINE-EUMEDICA 6 mg : BE152975. Geneesmiddel op medisch voorschrift. Voor een volledige informatie, gelieve de Samenvatting van de Kenmerken van het Product te raadplegen (beschikbaar op aanvraag).

SOM-BE-044 - December 2011

SA T URDAY

SOMATOSTATINE-EUMEDICA

9

R OO M «ASTR I D»

BASL / BLIC

Session one:

Session two:

• Moderators : S. Bourgeois, S. Van der Merwe

• Moderators : T. Gustot , A. GEERTS

9:00 A01 Impact of vitamin D deficiency on severity, inflammation and fibrosis

11:00 A07 A role for autophagy during hepatic stellate cell activation.

in alcoholic liver disease.

E. Trépo (1), R. Ouziel (1), P. Pradat (2), Y. Momozawa (3), E. Quertinmont (1), C. Gervy (1), T. Gustot (1), D. Degré (1), V. Vercruysse (1), P. Deltenre (4), B. Gulbis (1), D. Franchimont (1), J. Devière (1), A. Lemmers (1), C. Moreno (1) / [1] ULB Erasme, Brussels, [2] La Croix-Rousse Hospital, Lyon, France, [3] ULg [4] Hôpital de Jolimont, Haine-Saint-Paul

L.F. Thoen (1), E.L. Guimarães (1), L. Dollé (1), I. Mannaerts (1), M. Najimi (2), E. Sokal (2), L.A. Van Grunsven (1) / [1] UZ Brussel, [2] UCL St Luc, Brussels

11:15 A08 Use of Early-TIPS for High-Risk Variceal Bleeding. Results of a postRCT Surveillance study.

W. Laleman (1), M. Di Pascoli (2), J.C. Garcia-Pagan (2), K. Caca (3), C. Bureau (4), B. Appenrodt (5), A. Luca (6), A. Zipprich (7), J. Abraldes (2), F. Nevens (1), J.P. Vinel (4), J. Bosch (2) / [1] Kuleuven, [2] Hospital Clinic, Barcelona, Spain, [3] Klinikum Ludwigsburg, Germany, [4] Hôpital Purpan, Toulouse, France, [5] University Hospital, Bonn, Germany, [6] Istituto Mediterraneo, Palermo, Italy, [7] Wittenberg Klinik, Halle, Germany

9:15 A02 Keratin 19: a key role player in the invasion of human hepatocellular carcinomas.

O. Govaere (1), M. Komuta (1), B. Spee (1), A. Durnez (1), S. Vander Borght (1), C. Verslype (1), R. Aerts (1), B. Topal (1), J. Pirenne (1), F. Nevens (1), V.J. Desmet (1), L.R. Roberts (2), S.S. Thorgeirsson (3), T. Roskams (1) / [1] KULeuven, [2] Mayo Clinic, Rochester, USA, [3] National Institutes of Health (NIH), Bethesda, USA

11:30 A09 Kupffer cells modulate the ductular reaction in a mouse model of sclerosing Cholangitis.

J. Best (1), L. Dolle (2), N. Van Hul (3), L.P. Bechmann (1), S. Wing-Kin (4), F. Heindryckx (5), J.P. Sowa (1), L. Peeters (2), G. Kneiseler (1), I.A. Leclercq (6), I.O. Colle (5), A. Canbay (1), L.A. Van Grunsven (2) / [1] University Hospital Essen, Germany, [2] Uz Brussel, [3] Ucl St Luc, Brussels, [4] The Institute of Hepatology, Londen, UK, [5] UZGhent, [6] UCL St Luc

9:30 A03 Protective role of vitamin E on ccl4-pentobarbital induced liver damage in rats.

S. Wamutu (1), S. Francque (2), S. Chatterjee (3), G.W. Muyombya (1), E. Musisi (1), J. Weyler (2), E. Van Marck (2), G. Bimenya (1), P. Michielsen (2) / [1] Makerere University, Kampala, Uganda, [2] UZ Antwerpen

11:45 A10 Severe hyponatremia is the best predictor of mortality in cirrhosis and refractory ascites.

9:45 A04 Histopathological parameters are associated with both severity and

T. Sersté (1), T. Gustot (2), P.E. Rautou (3), C. Francoz (3), H. Njimi (2), F. Durand (3), D. Valla (3), D. Lebrec (3), R. Moreau (3) / [1] Ulb Saint-Pierre, Brussels, [2] ULB Erasme, Brussels, [3] Hôpital Beaujon, Clichy, France

survival in alcoholic hepatitis.

L. Verset, E. Trepo, N. Nagy, D. Degre, T. Gustot, J. Deviere, P. Demetter, C. Moreno / ULB Erasme, Brussels

10:00 A05 Chronic alcohol consumption induces hepatic insulin resistance

12:00 A11 Role of inflammation and insulin resistance in a new model of NASH: the foz/foz mice.

Unrelated to kupffer cell activation.

L. Poekes (1), N. Lanthier (1), G. Farrell (2), I. Leclercq (1), V. Legry (1) / [1] Ucl St Luc, Brussels, [2] The Canberra Hospital, Canberra, Australia

V. Lebrun, O. Molendi-Coste, P. Stärkel, I. Leclercq / UCL St Luc, Brussels

10:15 A06 Echocardiography for detection of Portopulmonary Hypertension in

12:15 A12 Normal versus elevated alt and ggt in an obese population, association with liver histology.

Liver Transplant Candidates.

A. Verrijken, S. Francque, I. Mertens, M. Ruppert, G. Hubens, E. Van Marck, P. Michielsen, L. Van Gaal / UZAntwerp

S. Raevens, K. Reyntjens, M. Depauw, A. Geerts, R. Troisi, F. Berrevoet, X. Rogiers, H. Van Vlierberghe, I. Colle / UZGent

10:30

coffee break

9

T h u r s d a y

BASL / BLIC

T h u r s d a y

R OO M «ASTR I D»

12:30 A13 Invited lecture : BASL-BLIC Spring Meeting lecture

“Liver transplantation in Belgium seen from the Eurotransplant view point: implications of MELD in Belgium.” J. Block /Eurotransplant, The Netherlands

13:00

14


Lunch


15

Session three:

• Moderators : J.P. Mulkay, I. Leclercq

9

R OO M «ASTR I D» 15:30

liver disease.

F. Temmerman, R. Vanslembrouck, W. Coudyzer, B. Bammens, W. Laleman, D. Cassiman, C. Verslype, W. Van Steenbergen , J. Van Pelt, J. Pirenne, F. Nevens / KULeuven

randomized, controlled Study.

14:15 A15 Role of angiogenesis and oxidative stress in a db/db mouse model for non-alcoholic Steatohepatitis.

S. Coulon (1), N. Rohr-Udilova (2), F. Heindryckx (1), C. Vansteenkiste (1), L. Libbrecht (1), H. Van Vlierberghe (1), A. Geerts (1), M. Peck- Radosavljevic (2), I. Colle (1) / [1] UZGent, [2] Medical University of Vienna, Austria

14:30 A16 Enhanced Sepsis-Associated Mortality of Patients with Cirrhosis in ICU: EPIC II study.

coffee break

16:00 A20 Search for an objective parameter of the severity of polycystic

14:00 A14 Efficacy of everolimus in 719 liver transplant recipients: a F. Nevens (1), P. De Simone (2), L. De Carlis (3), H.J. Metselaar (4), S. Beckebaum (5), F. Saliba (6), S. Jonas (7), D. Sudan (8), L. Fischer (9), J. Fung (10) / [1] Kuleuven, [2] Universitaria Pisana, Italy, [3] Niguarda Cà Granda Hospital, Milano, Italy, [4] Erasmus Medical Center, Rotterdam, Netherlands, [5] University DuisburgEssen, Germany, [6] Hôpital Paul Brousse, Villejuif, France, [7] University Hospital, Leipzig, Germany, [8] Duke University Medical Centre, Durham, U.S.A. [9] Universitätsklinikum, Hamburg Eppendorf, Germany, [10] Cleveland Clinic, Cleveland, U.S.A.

BASL / BLIC

9

T h u r s d a y

BASL / BLIC

T h u r s d a y

R OO M «ASTR I D»

16:15 A21 Outcome after liver transplantation using dcd donors: a singlecenter experience.

D. Monbaliu, J. Francois, S. Vandenbussche, R. Aerts, W. Laleman, C. Verslype, S. Vandermerwe, W. Van Steenbergen, D. Cassiman, F. Nevens, J. Pirenne / KULeuven

16:30 A22 Invited lecture: Marc Hautekeete Lecture

•

Moderators : R. Debruyne, D. Cassiman

17:15

“ What you should know about pediatric hepatology” G. Mieli-Vergani / London, UK BASL awards for the best basic and clinical work presented

T. Gustot, H. Njimi, F. Taccone, C. Moreno, J.L. Vincent / Ulb Erasme, Brussels

14:45 A17 Increased intrahepatic resistance in steatosis by endothelial dysfunction and microvascular changes.

S. Francque (1), W. Laleman (2), L. Verbeke (2), C. Van Steenkiste (3), C. Casteleyn (1), W. Kwanten (1), C. Van Dijck (1), M. D’hondt (1), A. Ramon (1), W. Vermeulen (1), B. De Winter (1), E. Van Marck (1), P. Pelckmans (1), P. Michielsen (1) / [1] UZAntwerpen, [2] KULeuven, [3] UZgent

15:00 A18 Efficacy of boceprevir in patients with null responses to peginterferon/ribavirin: the provide study.

Y. Horsmans (1), I. Jacobson (2), J. Vierling (3), S. Flamm (4), S. Gordon (5), E. Lawitz (6), J.P. Bronowicki (7), M. Davis (8), E. Yoshida (9), L. Pedicone (10), W. Deng (10), M. Treitel (10), C. Brass (10), J. Albrecht (10), F. Poordad (11) / [1] Ucl St Luc, Brussels, [2] Weill Cornell Medical College, New York, Usa, [3] Baylor College of Medicine, Houston, USA, [4] Northwestern Feinberg School of Medicine, Chicago, USA, [5] Henry Ford Hospital, Detroit, USA, [6] Alamo Medical Research, San Antonio, USA, [7] University Henri Poincare, Vandoeuvre-lès-Nancy, France, [8] South Florida Center of Gastroenterology, Wellington, USA, [9] University of British Columbia and Vancouver General Hospital, Canada, [10] Merck, Whitehouse Station, USA, [11] CedarsSinai Medical Center, Los Angeles, USA

15:15 A19 Resource use and cost of hepatitis C related care in Belgium.

F. Nevens (1), I. Colle (2), P. Michielsen (3), G. Robaeys (4), C. Moreno (5), K. Caekelbergh (6), M. Lamotte (6), V. Wyffels (7) / [1] Kuleuven, [2] Uzgent, [3] Uz Antwerpen, [4] Zol, Genk, [5] Ulb Erasme, Brussels, [6] IMS Consulting Group, Vilvoorde, [7] Janssen-Cilag NV, Beerse

16



17

15:30 – 16:00 BASL / BLIC Poster Session

9

R OO M «ASTR I D»

T. Baumert (1), C. Coltescu (1), M. Audet (1), S. Dritsas (1), P. Lutun (1), P. Wolf (1), M. Doffoel (1), F. Habersetzer (1) / [1] Notre Dame, Charleroi, [2] Hôpitaux Universitaires, Strasbourg, France

A33 Prospective randomized double blind placebo controled study on somatostatin in liver transplantation.

• REVIEWER : D. Ysebaert, J. Delwaide

A23

Expression of inflammatory and angiogenic factors in the serum of patients with steatosis and NASH. S. Coulon (1), S. Francque (2), A. Geerts (1), A. Verrijken (2), B.. Blomme (1), F. Heindryckx (1), H. Van Vlierberghe (1), L. Vangaal (2), I. Colle (1) / [1] UZ Gent, [2] UZ Antwerpen

A24

Risk factors of bleeding and clinical implications in patients undergoing liver Transplantation.

M. Esmat Gamil, F. Nevens, H. Van Malenstein, M. Verhaegen, B. Desschans, D. Monbaliu, R. Aerts, W. Laleman, D. Cassiman, C. Verslype, W. Van Steenbergen, J. Pirenne / KULeuven

A25

Significance of primary poor function (ppf) for the prognosis after liver Transplantation.

M. Sainz-Barriga (1), E. De Wolf (1), F. Berrevoet (1), X. Rogiers (1), E. Codarin (2), G. Tell (2), H. Reynaert (3), I. Colle (1), R. Troisi (1) / [1] Uz Gent, [2] University of Udine, Italy, [3] Uz Brussel

A34 HBsAg levels in nucleos(t)ide analogue suppressed HBeAg negative patients and HBsAg carriers.

E. Ho, S. Francque, M. Ieven, D. Ursi, V. Van Hoof, P. Michielsen / UZAntwerpen

A35

ormalisation of N-glycosylation after liver transplantation: a proof N of concept.

A36

Portopulmonary Hypertension: Has the prognosis improved ?

A37

Infection of N-Butyl-2-Cyanoacrylate in gastric varices as a cause for recurrent sepsis.

X. Verhelst (1), B. Blomme (1), E. Padalko (1), I. Colle (1), A. Geerts (1), R. Troisi (1), X. Rogiers (1), N. Callewaert (2), H. Van Vlierberghe (1) / [1] UZ Gent, [2] VIB, Gent

A38

A28 The value of minimally invasive surgery for the treatment of

A29 Surveillance for hepatocellular carcinoma (HCC) and

A39

gastroesophageal varices (GEV) by Belgian gastroenterologists. P. Michielsen (1), J. Delwaide (2), C. Degalocsy (3) / [1] UZ Antwerpen, [2] ULg , [3] Hôpitaux Iris Sud Bracops, Brussels

A30

A40

M. Komuta, O. Govaere, V. Vandecaveye, W. Van Steenbergen, C. Verslype, J. Pirenne, R. Aerts, F. Nevens, B. Topal, T. Roskams / KULeuven

A32 MELD score and the need for liver transplantation in patients with acute severe autoimmune hepatitis.

G. Mavrogenis (1), P. Warzee (2), C. Dabo (1), M.L. Woehl (1), B. Ellero (1), E. Sauleau (1), 18


Retinoic acid deficiency contributes to the inflammatory status of alcoholic cirrhotic Patients. R. Ouziel (1), E. Trépo (1), A. Cremer (1), C. Moreno (1), D. Degré (1), F. Cotton (1), V. Vercruysse (1), E. Quertinmont (1), J. Devière (1), A. Lemmers (1), T. Gustot (1) / [1] Ulb Erasme, Brussels

J. Liem, F. Willemssen / Erasmus Medical Center, Rotterdam, Netherlands

different cholangiocyte phenotype.

Morbidity and risk factors of conversions in 223 consecutive Laparoscopic liver resections. R. Montalti, M. Sainz-Barriga, A. Vanlander, F. Berrevoet, X. Rogier, R.I. Troisi / UZ Gent

Differentiation of focal cystic liver lesions based on radiological imaging findings.

A31 Histological diversity in cholangiocellular carcinoma reflects the

Side Population in human hepatic carcinomas reflects a population with progenitor cell features. O. Govaere (1), M. Komuta (1), K. Van Den Eynde (1), J. Wouters (1), A. Van Den Broeck (1), C. Empsen (2), L. Gremeaux (1), R. Aerts (1), L. Van Grunsven (2), B. Topal (1), H. Vankelecom (1), T. Roskams (1) / [1] Kuleuven, [2] Uz Brussel

hepatocellular Carcinoma.

H. Topal, J. Tiek, S. Fieuws, R. Aerts, C. Verslype, J.. Pirenne, T. Roskams, F. Nevens, B. Topal / KULeuven

J. Verbeek, D. Monbaliu , S. Van Der Merwe, D. Cassiman, W. Laleman, C. Verslype, W. Van Steenbergen, R. Aerts, J. Pirenne, M. Delcroix, F. Nevens / KULeuven

F. Ausloos (1), S. Hillaire (2), P. Bedossa (2), F. Bert (2), C. Moreno (3), A. Geubel (1), D. Valla (2), A. Plessier (2) / [1] Ucl St-Luc, Brussels, [2] Hôpital Beaujon, Clichy, France, [3] Ulb Erasme, Brussels

A27 Hepatitis E seroprevalence in Belgium.

F. Vanhoecke, T. Vanmaerken, M. Deboulle, A. Geerts, H. Van Vlierberghe, I. Colle, E. Padalko / UZ Gent

Need and timing of kidney in relation to liver transplantation in polycystic liver disease. F. Temmerman, T. Darius, J. Pirenne, D. Monbaliu, R. Aerts, B. Bammens, W. Laleman, D. Cassiman, C. Verslype, W. Van Steenbergen , D. Kuypers, F. Nevens / KULeuven

G. Uijtterhaegen, I. Haentjens, R. Troisi, G. Vanmaele, H. Van Vlierberghe, X. Rogiers / Uz Gent

A26

BASL / BLIC POSTER SESSION

9

T h u r s d a y


T h u r s d a y

R OO M «ASTR I D»

A41

Laparoscopic liver resections versus open approach: an intraoperative Cost-effectiveness analysis. R. Montalti, A. Verhaevert, L. De Gezelle , L. Louagie, X. Rogier, R.I. Troisi / Uz Gent

A42

Evaluation of transient elastography during active alcohol consumption and after withdrawal. V. Nguenang (1), A. Badaoui (2), E. Danse (1), C. Dragean (1), J.F. Rahier (1), P. Stärkel (1) / [1] Ucl St Luc, Brussels, [2] Ucl Mont-Godinne


19

Survival results of hepatectomies for colorectal metastasis using new strategies aiming R0-resection. A. Dili, J. Lemaire, G. Molle, B. Mansvelt, C. Bertrand / Hôpital De Jolimont, Haine-Saint-Paul

A44

Syncoilin is a true intermediate filament in mouse hepatic stellate cells. E. Van Rossen, Z. Liu, D. Blyweert, L. Van Grunsven, H. Reynaert / Uz Brussel

A45

Role of Class II HDACs during hepatic stellate cell activation and fibrosis. I. Mannaerts (1), N. Eysackers (1), K. Van Beneden (1), O. Onyema (1), A. Mai (2), L. Van Grunsen (1) / [1] Uz Brussel, [2] Sapienza University, Rome, Italy

9

R OO M «FAB I O LA»

OG-FWO

Session one:

• Moderators : P. VandenBerghe, J.P. Timmermans Invited lecture : “The eosinophil and the gastrointestinal tract- a 9.00 B01 friend or a foe?”

9

T h u r s d a y

A43


T h u r s d a y

R OO M «ASTR I D»

A. Straumann / Olten, Switzerland

9.35 B02 Adoptive transfer colitis model: validation by endoscopy and micro pet/ct.

M. Heylen, J. De Man, S. Staelens, S. Deleye, P. Pelckmans, T. Moreels, B. De Winter / UZAntwerpen

9.50 B03 Anti-inflammatory effect of vagus nerve through intestinal resident macrophages expressing a7nachr.

P.J. Gomez Pinilla (1), G. Matteoli (1), M. Di Giovangiulio (1), A. Nemethova (1), K. Lambaerts (1), S.H. Van Bree (2), C. Cailotto (2), G. Boeckxstaens (1) / [1] KULeuven, [2] Academic Medical Center, Amsterdam, The Netherlands

10.05 B04 Mas-related gene receptor mrgd is a modulator of mast cell recruitment in intestinal inflammation.

L.R. Avula, R. Buckinx, K. Alpaerts, D. Adriaensen, L. Van Nassauw, J.P. Timmermans / UZAntwerpen

10.20 B05 The Vagus Nerve As Modulator of Intestinal Immune Homeostasis. M. Di Giovangiulio, P.J. Gomez-Pinilla, C. Van Heijningen, K. Lambaerts, G. Matteoli, G. Boeckxstaens / KULeuven

10:35

coffee break

Session two :

• Moderators : R. Lefebvre, G. Boeckxstaens Invited lecture : “Analysis of the ibd kinome: potential 10.55 B06 applications.”

M. Peppelenbosch /Rotterdam, The Netherlands

11.30 B07 Origin of phase 3 of the migrating motor complex differs between lean and obese subjects.

E. Deloose, P. Janssen, M. Lannoo, B. Van Der Schueren, I. Depoortere, J. Tack / KULeuven

20



21

9


OG-FWO

Session foor:

11.45 B08 The effect of a bitter receptor agonist on food intake and satiation in healthy volunteers.

S. Verschueren, E. Deloose, S. Janssen, I. Depoortere, J. Tack, P. Janssen / KULeuven

12.00 B09 Role of vasoactive intestinal peptide (vip) and pacap in adipogenesis.

T. Arsenijevic, F. Gregoire, J. Cnudde, M. Waelbroeck, J. Perret, C. Delporte / ULB Erasme, Brussels

12.15 B10 Restricted feeding accelerates gastric emptying independent from Its effect on ghrelin secretion.

J. Laermans, K. Beckers, T. Thijs, S. Janssen, J. Tack, I. Depoortere / KULeuven

12:30

Lunch

Session three:

• Moderators : B. De Winter, J. Tack 14.00 B11 Invited lecture : “Ratting out ibs.” R. Van Den Wijngaard / Amsterdam, The Netherlands

14.35 B12 Experimental models to induce visceral hypersensitivity in rats.

• Moderators : I. Depoortere, J.M. Vanderwinden

16.00 B16 Mechanism of action of bay 41-2272 in gastrointestinal relaxation. S. Cosyns, R.A. Lefebvre / Heymans Institute of Pharmacology, Gent

9

T h u r s d a y

OG-FWO

T h u r s d a y


16.15 B17 Deep imaging in the gut wall: exploring tissue clearing with 1- and 2- photons excitation microscopy.

J.M. Vanderwinden, P. Hague, F. Bolletquivogne / ULB Erasme, Brussels

16.30 B18 Validation of the zebrafish mutant lessen for hirschsprung’s disease research.

L. Uyttebroek (1), I.I. Shepherd (2), G.. Hubens (1), J.P.. Timmermans (1), L. Van Nassauw (1) / [1] UZAntwerpen, [2] Emory University, Atlanta, USA

16.45 B19 Influence of corm-a1 on tnf-alpha-induced oxidative stress and apoptosis in mode-k cells.

D. Babu (1), O. De Backer (1), S. Soenen (2), K. Raemdonck (2), G. Leclercq (2), R. Motterlini (3), R.A. Lefebvre (1) / [1] Heymans Institute of Pharmacology, Gent, [2] UZGent, [3] INSERM U955, Créteil, France

17.00 B20 Impaired endoplasmic reticulum stress response in inflamed biobreeding rats.

T. Masaoka, S. Salim Rasoel, C. Vanormelingen, P. Vanden Berghe, J. Tack / KULeuven

A. Deiteren, W. Vermeulen, J. De Man, T. Moreels, P. Pelckmans, B. De Winter / UZAntwerpen

14.50 B13 A link between stress hormones, enteric nerve activity and fasting in mice.

K. Lowette, L. Roosen, J. Tack, P. Vanden Berghe /KULeuven

15.05 B14 Rectal sensitivity measurement: rectal mucosal capsaicin applications and rectal distensions.

S. Van Wanrooij, W. Vanbrabant, K. Lambaerts, M. Wouters, G. Boeckxstaens / KULeuven

15.20 B15 Long-lasting impaired mucosa integrity after esophageal perfusion with acid & weakly acidic solution.

N. Pardon (1), M. Vicario (2), H. Vanheel (1), T. Vanuytsel (1), K. Blondeau (1), M. Jimenez (3), J. Tack (1), R. Farré (1) / [1] KULeuven, [2] Hospital Universitari Valld’Hebron, Barcelona, Spain, [3] Universitat Autònoma de Barcelona, Spain

15:35

22

coffee break



23

9

R OO M «LE O PO LD I I I»

Belgian Pancreatic Club (BPC)

Session one:

Session two:

• Moderators : M. Delhaye, W. Van Steenbergen

• Moderators : P. Deprez, P. Pelckmans

09.00 T01 Invited lecture : “Diffusion-Weighted Magnetic Resonance Imaging

11.15 T07 Invited lecture : “Laparoscopic pancreatic resections.”

(DW-MRI) in pancreatic diseases.” C. Matos / ULB Erasme, Brussels

09.30 T02 How accurate is endoscopic ultrasound in the differentiation of cystic lesions of the pancreas?

E. Cesmeli, B. Pauwels, D. Laukens, M. De Vos / UZGent

09.45 T03 Diffusion-weighted magnetic resonance imaging and characterization of pancreatic fluid collections.

M. Arvanitakis, H. Duarte, S. El Bacha, A. Lemmers, E. Toussaint, P. Eisendrath, J. Devière, M. Delhaye, M.A. Bali, C. Matos / ULB Erasme, Brussels

10.00 T04 Is amoxicillin-clavulanate antibioprophylaxis before pancreatic cystic lesion EUS-FNA effective?

P. Leclercq (1), F. Xuereb (2), I. Mohammedi (3), E. Boselli (4), E. Zaoui (3), F. Fumex (3), C.Lefort (3), R. Legeron (2), D. Breilh (2), D. Ribeiro (3), B. Napoleon (3) / [1] CHC, Liège, [2] Hôpital Haut-Lévêque, Bordeaux, France, [3] Hôpital Privé Jean Mermoz, Lyon 08, France, [4] Hôpital Edouard Herriot, Lyon, France

10.15 T05 Evaluation of the nutritional status of patients with alcoholic chronic pancreatitis.

J. Rigaux, M. Arvanitakis, M. Delhaye, J. Devière / ULB Erasme, Brussels

C. Hubert / UCL St Luc, Brussels

9

T h u r s d a y

Belgian Pancreatic Club (BPC)

T h u r s d a y


11.45 T08 Intraductal tubulopapillary neoplasm of the pancreas: a rare and separate entity.

L. Verset, B. Doukoure, M. Arvanitakis, C. Matos, M.A. Bali, J. Closset, P. Loi, M. Delhaye, N. Nagy, P. Demetter / ULB Erasme, Brussels

12.00 T09 “Pancreatic mass of unknown origin.”

H. Vafa, M. Arvanitakis, P. Demetter, P. Eisendrath, E. Toussaint, J. Devière, M. Delhaye / ULB Erasme, Brussels

12.15 T10 “Obstructive jaundice from unknown origin in a 39 year old man.” A. Thooft, M.A. Bali, E. Coppens, M. Arvanitakis, J. Devière, P. Demetter, M. Delhaye / ULB Erasme, Brussels

12.30 T11 “Bile duct obstruction by an ampullary mass lesion of the papilla of Vater: a rare cause of benign biliary obstruction.” K. Nelissen, G. De Hertogh, W. Van Steenbergen / KULeuven

12.45 T12 “Severe pancreatitis of apparently unknown origin in a young female patient.”

W. Van Moerkercke, W. Van Steenbergen / KULeuven

10.30 T06 Mesopancreas: The “holy plane” of pancreatic resection for cancer contains 20% of all lymph nodes.

C. Bertrand, A. Dili, M.O. Peny, R. Gerard, G. Molle, B. Mansvelt / Hôpital de Jolimont, Haine-Saint-Paul

10:45

24

coffee break



25

G r o un d F l o o r

Thu r s d a y 9

ROOMS

ASTRID

FABIOLA

LEOPOLD III

MORNING

BASL / BLIC

OG - FWO

Belgian Pancreatic Club

CoFfee Break

10h30-11h00

10H35-10h55

10H45 -11h15

MORNING

BASL / BLIC

OG - FWO

Belgian Pancreatic Club

LUNCH

12h30 -14h00

12h30 -14h00

12h30 -14h00

HORIZON

Albert ii

Lobby Area ACCREDITATION ONLINE

Sat. Symposium BAYER

13H15 - 14H00

Sat. Symposium MSD

Afternoon

BASL / BLIC

OG - FWO

BSGIE

BIRD

CoFfee Break

15h15 - 15h45

15h35 - 16h00

15h30 - 16h00

15h45 - 16h00

Afternoon

BASL / BLIC

OG - FWO

BSGIE

BIRD

NUTRITION

ACCREDITATION ONLINE

15h30 - 16h00

15h30 - 16h00

BASL/BLIC POSTER SESSION

NUTRITION

RADIO FREQUENCY ABLATION (RFA)

Sat. Symposium GILEAD

Satellite Symposium CHIESI

7h45 - 8h30

F R I DA Y 1 0

LE V EL 3

12h30 - 13h15

17H30 - 18H15

MORNING

BGDO/Radio/ Patho/ Nuclear Med.

BIRD

CoFfee Break

10h15 -10h45

10h15 -10h40

10h30 -11h00

10h20-10h40

MORNING

BGDO

BIRD

Radiology/ Pathology

BeSPGHAN

Lunch

12h30 -14h00

12h30 -14h00

12h30 -14h00

12h30 -14h00

12h30 -14h00

BeSPGHAN G. A.

Sat. Sympo. ABBOTT

12h30 - 13h15

BeSPGHAN

GE Professional Ass.


10h15 -11h00

POSTER SESSION

13h15 - 14h00

Sat. Sympo. PFIZER

AFTERNOON COFFEE BREAK

16h00 -16h20

AFTERNOON

Plenary Session

Radio/Pathology

Plenary Session

15h40 -16h00

15h40 -16h00

15h40 -16h00

Plenary Session

Seven soc postgraduate course (BASL)

CoFfee Break

10h40 -11h00

10h40 -11h00

MORNING



Lunch

12h50 -14h15

12h50 -14h15

SS aatt uu rr ddaayy 161



SRBGE board

Sat. Sympo. THERASPHERE - NORDION

13h30 - 14h15

X x I Vrd • B e l g i a n W e e k o f

15h40 -16h00

POSTER SESSION

AC SRBGE

MORNING

AFTERNOON


Plenary Session AC Acta Gastroenterologica

18h00 - 18h45

S at u r d ay 11

BAUDOUIN

LE V EL 1

FF rr i i ddaayy 150

XXIV th Belgian Week of Gastroenterology

Pa l ac e ”

4 9

2012

“ Th e r m a e

T h u r s d a y

26

ostend

BrOHEE LECTURE Seven soc postgraG a s t r o e n t e r o l o g yduate • O o s tcourse e n d e , F e (BASL) b r uary

0 9 - 11 2 012

BrOHEE LECTURE ACCREDITATION ONLINE Seven soc postgraX x I V r d •(BASL) B e lg ian W e e k o f Gastr o e nte r o lo gy duate course

• O o s t e n d e , F e b r u a r y 0 9 - 11 2 012

27

Session one:

• Moderators : V. Lamy, J. Arts

Invited lecture : “Acute pancreatitis: diagnostic endoscopy.” 14.00 G01 P. Deprez / UCL St Luc

14.30 G02 The clip-traction-assisted technique – a new method for safe endoscopic submucosal dissection.

9

R OO M «Baud o uin» Session one:

• Moderators : D. Franchimont, M. Joossens

Invited lecture : “The microbial flora: A review on microbiology 14:00 I01 and techniques.” J. Raes / UZ Brussel

14:30 I02 Predominant dysbiosis in patients with ulcerative colitis is different from crohn’s disease patients.

B. Ayang, E. Kim, A. Mourin, H. Piessevaux, P. Deprez / UCL St Luc

K. Machiels, M. Joossens, J. Sabino, V. De Preter, I. Arijs, V. Ballet, K. Claes, J. Verhaegen, G. Van Assche, P. Rutgeerts, S. Vermeire / KULeuven

14.40 G03 Taking biopsies in endoscopic normally appearing oesophagus to exclude eosinophilic oesophagitis.

B. Hauser, T. Devreker, G. Veereman, E. De Greef, Y. Vandenplas / UZ Brussel

14:45 I03 TUDCA alleviates DSS-induced colitis by forcing IRE1 activity and reducing colonocyte apoptosis.

14.50 G04 Gastroesophageal reflux evaluation in adult patients affected by chronic cough.

L. Vandermeulen, D. Ummarino, B. Roosens, B. Hauser, Y. Vandenplas, D. Urbain / UZ Brussel

D. Laukens, L. Devisscher, P. Hindryckx, H. Peeters, M. De Vos / UZ Gent

15:00 I04 Repeated cycles of DSS inducing a chronically relapsing inflammation: a novel model to study fibrosis.

B. Breynaert (1), T. Dresselaers (2), J. Cremer (1), K. Van Steen (3), C. Perrier (1), S. Vermeire (1), P. Rutgeerts (1), J. Ceuppens (1), U. Himmelreich (2), G. Van Assche (1) / [1] KULeuven, [2] Biomedical NMR unit, Leuven, [3] ULg

15.00 G05 Invited lecture : “Acute pancreatitis: endoscopic therapy.” O. Le Moine / ULB Erasme, Brussels

15:30

coffee break

BIRD

9

T h u r s d a y

BSGIE

T h u r s d a y


15:15 I05 Invited lecture : “Bacterial handling and Autophagy in health and Disease.”

Session two:

K. Cadwell / New York, U.S.A.

• Moderators : P. Van der Spek, T. Moreels

15:45

16.00 G06 BSGIE 2008 grant winner: Chromoendoscopy versus virtual

Session two:

chromoendoscopy in ulcerative colitis: a randomized controlled trial.

R. Bisschops, T. Bessissow, F. Baert, M. Ferrante, V. Ballet, H. Willekens, I. Demedts, K. Geboes, G. De Hertogh, S. Vermeire, G. Van Assche, P. Rutgeerts / KULeuven

16.10 G07 Effect of national guidelines on quality of colonoscopy: a singlecentre analysis.

E. Macken, T. Van Hoof, N. Messaoudi, P. Pelckmans, T. Moreels / UZ Antwerpen

16.20 G08 The revival of unsedated colonoscopy through water infusion. B. Strubbe, S. Beeckman, M. De Vos, D. De Looze /UZ Gent

16.30 G09 A comparative study between insufflation with carbon dioxide, air or warm water during colonoscopy. E. Macken, T. Moreels / UZ Antwerpen

16.40 G10 Invited lecture : “Acute pancreatitis: endoscopic therapy of acute pseudocyst and Necrosis.” M. Barthet / Marseille, France

coffee break

• Moderators : S. Vermeire, C. Renaers

16: 00 I06 Contribution of genes underlying monogenic diseases with IBDlike symptoms to predisposition to IBD.

L. Amininejad (1), Y. Momozawa (2), B. Charloteaux (2), E. Trepo (1), M. Mni (2), E. Quertinmont (1), M. Abramowicz (1), J. Deviere (1), E. Louis (2), A. Van Gossum (1), M. Georges (2), D. Franchimont (1) / [1] ULB Erasme, Brussels, [2] ULg

16:15 I07 Restoration of Foxp3 regulatory T cell correlates with clinical response to anti-TNF therapy for IBD.

Z. Li, S. Vermeire, D. Bullens, M. Noman, M. Ferrante, P. Rutgeerts, J. Ceuppens, G. Vanassche / KULeuven

16:30 I08 Targeting metallothionein in DSS-colitis points to new therapeutic strategies for IBD patients.

L. Devisscher (1), P. Hindryckx (1), K. Olievier (1), H. Peeters (1), M. Lynes (2), C. Cuvelier (1), M. De Vos (1), D. Laukens (1) / [1] UZ Gent, [2] University of Connecticut, Storrs, U.S.A.

16:45 I09 Invited lecture : “ UC genetics and pathogenesis: How different is UC from CD?”

S. Danese / Milan, Italy

28



29

9

R OO M «ALB E RT I I»

NUTRITION

Session one:

Session two:

14:00 N01 Screening and predicting malnutrition in cancer patients

16:00 N07 Factors associated with Vitamin D insufficiency in a population of

• Moderators : D. Ysebaert, J.C. Preiser

• Moderators : N. Van DEWinkel, J.P. Thissen HIV-infected patients.

undergoing Radiotherapy.

N. Barthelemy, L. Trokay, A.F. Donneau, F. Princen, P. Coucke, A. Albert, M. Guillaume / ULg

14:15 N02 Higher food intake and appreciation with a new food delivery

Theodorou, T. Sersté, M. Van Gossum, S. De Wit / ULB St-Pierre, Brussels

16:15 N08 Nutritional deficiencies in pregnancy are frequent after bariatric surgery: a prospective cohort study.

system in a Belgian hospital.

I. Guelinckx (1), G. Vansant (1), S. Bel (1), S. Pauwels (1), C. Verbeke (2), T. Vanderheyden (3), R. Devlieger (2) / [1] KULeuven, [2] ZOL, Genk, [3] Sint Augustinus Ziekenhuis, Antwerpen

E. De Wit (1), P. Goeminne (2), C. Burtin (2), Y. Valcke (1) / [1] AZ Nikolaas, Sint-Niklaas, [2] KULeuven

14:30 N03 Is early oral energetic liquid diet dangerous in acute non surgical complicated diverticulitis?

16:30 N09 Effect of iv lipid emulsion containing soybean oil,medium chain

fatty acids and fish oil on the serum fatty acids profile in long term HPN patients.

G. Van Ooteghem, W. Margos, A. El Nawar, J.F. Gallez, A. Patris, J. Kirsch, A. Nakad / CH Wapi Notre Dame, Tournai

14:45 N04 Cost/Benefit of probiotics in acute infectious gastroenteritis : spend to save.

M. Arvanitakis, V. Lievin, A. Ballarin, A.Van Gossum / ULB Erasme, Brussels

16:50 N10 Treatment of a Patient With D-lactic Acidosis with Home Parenteral Nutrition.

Y. Vandenplas (1), S.G. Dehert (2), Probioticalstudygroup (3) / [1] UZ Brussel, [2] UZ Gent.

15:00 N05 Effects of an artificial hypercaloric and hyperproteic feeding on

nutritional status in post-surgery head and neck cancer patients.

K. Boeykens, I. Duysburgh / AZ Nikolaas

17:15 N11 U-shaped relationship between caloric intake and outcome of critically ill patients.

C. Malherbe , J. De Flines, A-M. Verbrugge , P. Demez, P. Moreau, N. Paquot / ULg

15:15 N06 Development of quality of care interventions for adult patients on

home parenteral nutrition (HPN) with a benign underlying disease using a two-round Delphi approach. M. Dreesen, V. Foulon, K. Vanhaecht, M. Hiele, L. De Pourcq, L. Pironi, A. Van Gossum, G. Wanten, J. P Baxter, F. Joly, C. Cuerda, L. Willems / KULeuven, Brussels, Paris, Bologna, Madrid, Maastricht

15:30

30

9

T h u r s d a y

NUTRITION

T h u r s d a y

R OO M «ALB E RT I I»

I. Carolina Reis Crosara, C. Melot, J.C. Preiser / ULB Erasme, Brussels

17:35 N12 Determination of a Simplified Method for Estimating Resting Energy Expenditure in Critically Ill Patients.

M. Hviid Simonsen (1,2), H. Steen Andreassen (2), J.C. Preiser (1) / [1]ULB Erasme, Brussels, [2] Aalborg University, Denmark

18:00

End of programme

coffee break



31

R OO M «Astrid»

BGDO/RADIOlogy/ PATHOlogy/ NUCLEAR MEDECINE

Session one:

• Moderators : E. Van Cutsem, P. Flamen 08:35 P01 Invited lecture : “Radiologic imaging in NET: pitfalll and challenges.”

R OO M «Astrid» Session two:

• Moderators : J.L. Van Laethem, M. Peeters 10:45 P05 Signet ring cells in esophageal and GE junction carcinomas: a study of biological behavior.

P. Nafteux, J. Dhaenens, G. De Hertogh, J. Moons, W. Coosemans, G. Decker, H. Decaluwe, D. Van Raemdonck, T. Lerut, P. De Leyn / KULeuven

L. Annet /UCL St Luc

09:00 P02 Invited lecture : “The diagnostic and therapeutic role of nuclear medicine in NET.”

10:55 P06 Advances in the treatment of zollinger-ellison syndrome. review of 45 cases and analysis of survival.

C. De Roose /KULeuven

N. Q. N. Doan (1), I. Borbath (1), P. Deprez (1), J.F. Gigot (1), P.J. Kestens (1), P. Maldague (2), D. Maiter (1), M. Schapira (3), S. Pauwels (1), R. Fiasse (1) / [1] UCL St Luc, Brussels, [2] Clinique St-Luc, Namur, [3] Hôpital de Jolimont, Haine-Saint-Paul

09:25 P03 Invited lecture : “Medical treatment of NET.” A. Hendlisz / ULB Bordet, Brussels

09:50 P04 Invited lecture : “Pathologic classification of NET.” 10:15

11:05 P07 Biopsies insufficiently predict final histology after endoscopic resection in Barrett’s neoplasia.

E. Werbrouck, G. De Hertogh, H. Willekens, X. Sagaert, R. Bisschops / KULeuven

coffee break

F r i d a y

11:15 P08 I-scan detects more polyps in Lynch Syndrome patients: a prospective controlled randomized trial.

F RIDAY

1 0

G. Rindi / Rome, Italy

BGDO

R. Bisschops, S. Tejpar, H. Willekens, G. De Hertogh, E. Van Cutsem / KULeuven

Highlights of the year 2011

1 0

• Moderators : I. Borbath, E. Van Cutsem 11:30 P09 Invited lecture : “Colorectal cancer.” G. Demoulin / ULg

11:50 P10 Invited lecture : “HepatoBiliopancreatic cancer.” C. Verslype /KULeuven.

12:10 P11 Invited lecture : “ Oesophagastric cancer.” K. Geboes /UZGent

12:30

32


Lunch


33


RADIOLOLOGY / PATHOLOGY

Session one:

• Moderators : E. Danse, G. De Hertog 11:00 P12 Pancreatic Endocrine Tumors: An Overview Of Typical And Atypical Presentations At Imaging.

K. Buccauw, D. Vanbeckevoort, D. Bielen / KULeuven

11:15

P13 Peritoneal calcified nodule: a condition we do not have to underestimate.

E. Danse, D. Leonard, A. Dragean, A. Kartheuser, A. Jouret-Mourin / UCL St Luc, Brussels

11:30 P14 Fluctuating cholestasis in a 45-years-old man with polycystic kidney disease.

L. Verset, N. Nagy, C. Moreno, M. Adler, C. Matos, P. Demetter / Ulb Erasme, Brussels


RADIOLOLOGY / PATHOLOGY

15:15 P21 Hepatic sinusoidal obstruction syndrome reduces effect of oxaliplatin in colorectal liver metastases.

C. Vreuls (1), M. Van Den Broek (1), A. Winstanley (2), G. Koek (1), E. Wisse (1), C. Dejong (1), S. Olde Damink (1), F. Bosman (3), A. Driessen (1) / [1] Maastricht University Medical Centre, Netherlands, [2] University College London, UK, [3] Erasmus Medical Center, Rotterdam, Netherlands

15:30 P22 Auto-immune gastritis characteristics in a large series of patients with auto-immune thyroiditis.

H. Valdes, M. Tomegarcia, L. Lutteri, C. Reenaers, M. Polus, V. Geenen, E. Louis, A. Beckers / ULg

15:45 P23 Invited lecture : “Correct histopathological staging of colorectal cancer: a challenging issue.” P. Demetter / ULB Erasme, Brussels

12:00 P16 Which grading system to be applied in pancreatic endocrine tumors: semi-quantitative vs quantitative.

B. Weynand, I. Borbath, C. Sempoux, J.F. Gigot, A. Jouret-Mourin / UCL St-Luc, Brussels

12:15

Lunch

1 0

F RIDAY

H. Dano, I. Theate , M. Van Den Eynde, M. Lambert, J.F. Rahier , L. Annet , C. Sempoux / UCL St Luc, Brussels

F r i d a y

1 0

11:45 P15 Unusual liver masses in two women.

Session two:

• Moderators : N. Nagy, A. Hoorens

14:00 P17 Invited lecture : “Lymphatics in IBD, friend or foe.”

J.F. Rahier / UCL Mt Godinne

14:30 P18 Endoscopic Ultrasound-Guided Fine-Needle Aspiration in the Diagnosis of Pancreatic Lymphomas.

S. Saadi, I. Theate, B. Weynand / UCL St Luc, Brussels

14:45 P19 Pathological response after preoperative treatment for resectable liver colorectal metastases.

G. Pairet, V. Lannoy, A. Jouret-Mourin, Y. Humblet, C. Hubert, J.F. Gigot, C. Sempoux, M. Van Den Eynde / UCL St-Luc, Brussels

15:00 P20 Barrett’s metaplasia, dysplasia and esophageal adenocarcinoma : an inadequate antitumour immunity ?

J. Somja, S. Demoulin, L. Herman, M. Herfs, P. Roncarati, E. Dortu, E. Louis, P. Hubert, P. Delvenne / ULg

34



35

R OO M «Baud o uin»

PEDIATRY - BeSPGHAN

R OO M «Baud o uin»

PEDIATRY - BeSPGHAN

Session one:

Session two:

08:30 E01 Invited lecture : “IBD and probiotics.”

10:40 E08 Invited lecture : “Composition and functions of the human gut

• Moderators : Y. Vandenplas, P. Bontems G. Veereman / UZ Brussel / University Paris Descartes, France

08:50 E02 New onset food allergy in children after liver transplantation.

S. Vander Plaetsen, K. Robben, S. Van Biervliet, S. Vande Velde, M. Van Winckel, R. De Bruyne / UZ Gent

09:00 E03 Factors determining therapeutic strategy at diagnosis and evolution of disease severity in a cohort of pediatric patients with Crohn’s disease.

E. Degreef / UZ Brussel and Belcro study group

09:10 E04 Invited lecture : “Obesity, type 2 diabetes and gut microbiota.” 1 0

10:00 E06 Extra-intestinal manifestations of Crohn’s disease in children:

A. Vael /KLINA Hospital, Antwerp

involvement of skin and joint.

microbiota: novel Insights.”

F. Guarner / Barcelona, Spain

11:05 E09 Endoscopic ultrasound to improve the management of bowel dysfunctions in children with Hirschprung.

T. Claeys, M. Miserez, A. Vandenbosch, M. Hiele, P. Schurmans, I. Hoffman / KULeuven

11:15 E10 Safety and cost of Inflixmab for the treatment of Belgian pediatric patients with Crohn’s disease.

E. Degreef /UZ Brussels and Belcro study group

11:25 E11 Invited lecture : “Maastricht 4 - new or old treatments for Belgium.” A. Burette, CHIREC/sites de la Basilique & E. Cavell, Brussels

F r i d a y

09:35 E05 Invited lecture : “Asthma and the intestinal microbiota.”

F RIDAY

P. D. Cani / Research associate FRS-FNRS , UCL , LDRI, Metabolism and Nutrition research group

• Moderators : F. Mana, R. Ntounda

11:45 E12 Invited lecture : « H. pylori: a fairytale. » S. Cadranel / HUDERF Brussels

12:00 – 13:00 BeSPGHAN General Assembly.

C. Buyck, C. Wouters, I. Hoffman / KULeuven

10:10 E07 Results of anti-reflux surgery after primary anastomosis for

1 0

esophageal atresia.

N. Deferm, W. Coosemans, P. Deleyn, P. Nafteux, D. Vanraemdonck, I. Hoffman, T. Lerut, H. Decaluwe / KULeuven

10:20

36

coffee break



37

20 mg 40 mg

Choosing

28 tabl.

€ 13,57 € 20,87

tabl. 56 tabl.

€ 19,21 € 30,07

tabl € 30,18 € 48,63 100 tabl.

efficacy and safety is choosing Pantomed . ®

www.rs-communication.be

100% worthy of your trust NAAM VAN HET GENEESMIDDEL Pantomed 20 mg maagsapresistente tabletten, Pantomed 40 mg maagsapresistente tabletten. KWALITATIEVE EN KWANTITATIEVE SAMENSTELLING Eén maagsapresistente tablet van 20 mg en één maagsapresistente tablet van 40 mg bevatten respectievelijk 20 mg pantoprazol (als 22,6 mg pantoprazol-natrium-sesquihydraat) en 40 mg pantoprazol (als 45,10 mg pantoprazol-natrium-sesquihydraat). FARMACEUTISCHE VORM Maagsapresistente tablet. Een gele, ovale, biconvexe, filmomhulde tablet, aan één zijde bedrukt met “P20” (voor Pantomed 20mg) en “P40” (voor Pantomed 40mg) in bruine inkt. THERAPEUTISCHE INDICATIES PANTOMED 20 mg: - Behandeling van lichte refluxaandoeningen en ermee geassocieerde symptomen (bv. pyrosis, zuurregurgitatie, pijn bij het slikken). - Langetermijnbehandeling en preventie van recidieven van refluxoesofagitis. - Preventie van gastroduodenale zweren geïnduceerd door niet-selectieve niet-steroïdale anti inflammatoire geneesmiddelen (NSAIDs) bij risicopatiënten die een continue behandeling met NSAIDs vereisen. PANTOMED 40 mg: - matige en ernstige refluxoesofagitis - bij patiënten met peptische ulcera in combinatie met twee geschikte antibiotica (zie “Dosering”) voor de eradicatie van H. pylori, met de bedoeling recidieven van duodenum- en maagulcus, veroorzaakt door dit micro-organisme, te verminderen. - duodenumulcus - maagulcus - Zollinger-Ellison syndroom en andere pathologische hypersecretoire aandoeningen. DOSERING EN WIJZE VAN TOEDIENING PANTOMED 20 mg: Aanbevolen dosering: Volwassenen en adolescenten ouder dan 12 jaar: Lichte refluxaandoeningen en ermee geassocieerde symptomen (bv. pyrosis, zuurregurgitatie, pijn bij het slikken) De aanbevolen orale dosering bedraagt één maagsapresistente tablet Pantomed 20 mg per dag. Verlichting van de symptomen wordt meestal bekomen binnen de 2 tot 4 weken. Voor de genezing van een ermee gepaard gaande oesofagitis is gewoonlijk een behandelingsduur van 4 weken vereist. Indien dit niet volstaat, zal genezing normaal bekomen worden na een bijkomende behandeling van 4 weken. Eens de symptomen zijn verdwenen, kunnen opnieuw optredende symptomen gecontroleerd worden door gebruik te maken van een “gebruik volgens noodzaak” regime van 20 mg éénmaal per dag, wanneer nodig. Een overschakeling naar een continue therapie kan overwogen worden wanneer er geen voldoende symptoomcontrole behouden kan worden met een “gebruik volgens noodzaak” regime. Langetermijnbehandeling en preventie van recidieven van refluxoesofagitis. Een onderhoudsdosis van één maagsapresistente tablet Pantomed 20 mg per dag wordt aanbevolen voor langetermijnbehandeling. Indien een recidief optreedt, zal deze dosis verhoogd worden tot 40 mg pantoprazol per dag. Pantomed 40 mg is hiervoor beschikbaar. Na genezing van het recidief kan de dosering opnieuw gereduceerd worden tot 20 mg pantoprazol. Volwassenen: Preventie van gastroduodenale zweren geïnduceerd door niet-selectieve niet-steroïdale anti inflammatoire geneesmiddelen (NSAIDs) bij risicopatiënten die een langdurige behandeling met NSAIDs vereisen. De aanbevolen orale dosering bedraagt één maagsapresistente tablet Pantomed 20 mg per dag. Kinderen onder de 12 jaar: Pantomed wordt niet aangeraden voor gebruik bij kinderen onder de 12 jaar wegens te weinig gegevens binnen deze leeftijdsgroep. Opmerking: Bij patiënten met een ernstige leverbeschadiging mag de dagelijkse dosis van 20 mg pantoprazol niet overschreden worden. Er is geen dosisaanpassing nodig bij ouderen of bij patiënten met een gestoorde nierfunctie. Algemene instructies: Pantomed 20 mg maagsapresistente tabletten mogen niet gekauwd of geplet worden en moeten in hun geheel met een hoeveelheid water ingenomen worden vóór een maaltijd. PANTOMED 40 mg: Aanbevolen dosering: Volwassenen en adolescenten ouder dan 12 jaar: Behandeling van matige en ernstige refluxoesofagitis. Eén tablet Pantomed per dag. In individuele gevallen mag de dosis worden verdubbeld (verhogen tot 2 tabletten Pantomed per dag), vooral wanneer andere behandelingen niet doeltreffend waren. Volwassenen: Eradicatie van H. pylori in combinatie met twee geschikte antibiotica. Bij Helicobacter pylori positieve patiënten met maag- en duodenumzweren, dient eradicatie van de bacterie bekomen te worden via een combinatietherapie. Afhankelijk van het resistentiepatroon, kunnen de volgende combinaties aangeraden worden voor de eradicatie van H. pylori: a) tweemaal daags 1 tablet Pantomed + tweemaal daags 1.000 mg amoxicilline + tweemaal daags 500 mg clarithromycine b) tweemaal daags 1 tablet Pantomed + tweemaal daags 500 mg metronidazol + tweemaal daags 500 mg clarithromycine c) tweemaal daags 1 tablet Pantomed + tweemaal daags 1.000 mg amoxicilline + tweemaal daags 500 mg metronidazol. Indien de combinatietherapie geen optie is, bv. de patiënt is Helicobacter pylori negatief, dienen de doseringsaanbevelingen voor Pantomed monotherapie gevolgd te worden: Behandeling van maag- en duodenumulcus. Eén tablet Pantomed per dag. In individuele gevallen mag de dosis worden verdubbeld (verhogen tot 2 tabletten Pantomed per dag), vooral wanneer andere behandelingen niet doeltreffend waren. Zollinger-Ellison syndroom en andere pathologische hypersecretoire aandoeningen. Bij een langetermijnbehandeling van het Zollinger-Ellison syndroom en andere pathologische hypersecretoire aandoeningen, zullen de patiënten hun behandeling starten met een dagelijkse dosis van 80 mg (dit zijn 2 tabletten Pantomed 40 mg). Daarna kan de dosis zoals nodig verhoogd of verlaagd worden aan de hand van zuurtegraadbepalingen. Wanneer de dagelijkse dosis meer dan 80 mg bedraagt, dient deze over 2 innames per dag gespreid te worden. Een tijdelijke verhoging van de dosering boven 160 mg pantoprazol is mogelijk, maar deze mag niet langer dan nodig voor een adequate controle van de zuurtegraad toegediend worden. Bij het Zollinger-Ellison syndroom en andere pathologische hypersecretoire aandoeningen is de behandelingsduur niet beperkt en dient aangepast te worden aan de klinische behoeftes. Kinderen onder de 12 jaar: Pantomed wordt niet aangeraden voor gebruik bij kinderen onder de 12 jaar wegens te weinig gegevens binnen deze leeftijdsgroep. Speciale populaties: Bij patiënten met een ernstige leverbeschadiging dient de dosis gereduceerd te worden tot 1 tablet (40 mg pantoprazol) om de 2 dagen. Daarenboven zullen bij deze patiënten tijdens een behandeling met Pantomed de leverenzymen regelmatig gecontroleerd worden. In geval van gestegen leverenzymen dient de behandeling met Pantomed stopgezet te worden. De dagelijkse dosis van 40 mg pantoprazol mag niet overschreden worden bij bejaarde patiënten of bij patiënten met een gestoorde nierfunctie. Een uitzondering hierop is de combinatietherapie voor H. pylori eradicatie, waar ook bij oudere patiënten gedurende 1 week de normaal voorziene dosis pantoprazol (2 x 40 mg/dag) zal toegepast worden. Algemene instructies: Pantomed tabletten mogen niet gekauwd of geplet worden en moeten in hun geheel met een hoeveelheid water ingenomen worden 1 uur vóór het ontbijt. In de combinatietherapie voor eradicatie van Helicobacter pylori wordt de tweede tablet Pantomed vóór het avondeten ingenomen. De combinatietherapie duurt in het algemeen 7 dagen en kan verlengd worden tot maximaal 2 weken. Indien, teneinde de genezing van de ulcera te verzekeren, een verdere behandeling met pantoprazol geïndiceerd is, dienen de doseringsaanbevelingen voor de behandeling van duodenum- en maagulcera gevolgd te worden. Een duodenumulcus geneest doorgaans binnen de 2 weken. Indien een behandeling gedurende 2 weken niet voldoende is, zal in vrijwel alle gevallen volledige genezing bekomen worden na een bijkomende behandeling van 2 weken. Voor de behandeling van maagulcera en refluxoesofagitis is meestal een behandelingsduur van 4 weken vereist. Zoniet zal volledige genezing gewoonlijk bekomen worden na een bijkomende therapie van 4 weken. CONTRA-INDICATIES PANTOMED 20 mg: Pantomed 20 mg mag niet gebruikt worden in geval van gekende overgevoeligheid voor één van de bestanddelen van Pantomed 20 mg. Pantoprazol, zoals andere PPIs, mag niet tegelijkertijd met atazanavir worden toegediend. PANTOMED 40 mg: Pantomed mag in het algemeen niet gebruikt worden in geval van gekende overgevoeligheid voor één van de bestanddelen van Pantomed of voor één van de combinatieproducten. Pantomed zal in de combinatietherapie voor eradicatie van H. pylori bij patiënten met matige tot ernstige lever- of nierinsufficiëntie niet gebruikt worden, aangezien tot nog toe geen gegevens beschikbaar zijn over de werking en de veiligheid van Pantomed in de combinatietherapie bij deze patiënten. Pantoprazol, zoals andere PPIs, mag niet tegelijkertijd met atazanavir worden toegediend. BIJWERKINGEN (Vaak (≥ 1/100 tot < 1/10), Soms (≥ 1/1.000 tot < 1/100), Zelden (≥ 1/10.000 tot < 1/1.000), Zeer zelden(< 1/10.000), niet bekend (kan met de beschikbare gegevens niet worden bepaald). Onderzoeken: Zeer zelden: Verhoogde leverenzymen (transaminasen, γ-GT); verhoogde triglyceriden; verhoogde lichaamstemperatuur; Bloed- en lymfestelselaandoeningen: Zeer zelden: leukopenie; trombocytopenie; Zenuwstelselaandoeningen: Vaak: hoofdpijn – Soms : duizeligheid; stoornissen van het gezichtsvermogen (wazig zien); Maagdarmstelsel aandoeningen: Vaak: hoogdigestieve pijn, diarree, constipatie, flatulentie – Soms: nausea / braken – Zelden: droge mond; Nier- en urinewegaandoeningen: Zeer zelden: interstitiële nefritis; Huid- en onderhuidaandoeningen: Soms: Allergische reacties zoals pruritus en huidrash – Zeer zelden: urticaria; angio-oedeem; ernstige huidreacties zoals het syndroom van Stevens-Johnson, erythema multiforme, syndroom van Lyell; fotosensibiliteit; Skeletspierstelsel- en bindweefselaandoeningen: Zelden: Artralgie – Zeer zelden: myalgie; Algemene aandoeningen en toedieningsplaatsstoornissen: Zeer zelden: Tromboflebitis op de plaats van injectie, Perifeer oedeem; Immuunsysteem-aandoeningen: Zeer zelden: Anafylactische reacties, inclusief anafylactische shock; Lever- en galaandoeningen: Zeer zelden: Ernstige hepatocellulaire beschadiging leidend tot icterus, met of zonder leverfalen; Psychische stoornissen: Zelden: Depressie, hallucinatie, desoriëntatie en verwardheid, met name bij vatbare patiënten, zowel als verergering van deze symptomen indien voorafbestaand. AARD EN INHOUD VAN DE VERPAKKINGEN Verpakkingen: flesjes (HDPE-fles met LDPE sluiting) en blisterverpakkingen (Alu/Alu blisterverpakkingen zonder kartonnen versteviging) met: 28, 56, 100 maagsapresistente tabletten. Hospitaalverpakkingen: blisterverpakkingen (Alu/Alu blisterverpakkingen zonder kartonnen versteviging) met 50 maagsapresistente tabletten. HOUDER VAN DE VERGUNNING VOOR HET IN DE HANDEL BRENGEN Nycomed Belgium , Gentsesteenweg 615, 1080 Brussel, België. AFLEVERING Geneesmiddel op medisch voorschrift. NUMMER(S) VAN DE VERGUNNING VOOR HET IN DE HANDEL BRENGEN Blisterverpakking: BE318254. Fles: BE318263 DATUM VAN HERZIENING VAN DE TEKST 08/2011. PM/PZ/10/007/NF

R OO M «Fabi o la »

Bird

R OO M «Fabi o la»

Bird

Session one:

• Moderators : M. Ferrante, J.F. Rahier

11:00 I17 Predictors of complicated disease in Crohn’s disease and ulcerative colitis.

E. Hoefkens, M. Ferrante, T. Bessissow, I. Cleynen, P. Rutgeerts, G. Van Assche, S. Vermeire / KULeuven

08:30 I10 Invited lecture : “Personalized medicine: optimizing anti-TNF therapies (trough levels).” F. Baert /HH Ziekenhuis Roeselaere

11:15 I18 Prognostic value of serologic and histologic markers on long-term outcomes in ulcerative colitis.

09:00 I11 Cotreatment with adalimumab (ADA) may be more effective than

T. Bessissow, B. Lemmens, M. Ferrante, R. Bisschops, K. Geboes, G. Van Assche, S. Vermeire, P. Rutgeerts, G. De Hertogh / KULeuven

ADA monotherapy in Crohn’s disease (CD).

C. Reenaers (1), E. Louis (1), J. Belaiche (1), S. Keshav (2), S. Travis (2) / [1] ULg, [2] John Radcliffe Hospital, Oxford, UK

11:30 I19 Invited lecture : “New scores in IBD: the disability index and Lémann score.”

09:15 I12 Point of care quantification of faecal calprotectin with the Quantum Blue rapid test.

L. Coorevits, F. Baert, H. Vanpoucke / H. Hart Hospital, Roseselare

L. Peyrin-Biroulet / Nancy, France

12:00

End of programme

09:30 I13 Monitoring of CRP and calprotectin to predict relapse in Crohn’s 1 0 F RIDAY

12:00 – 12:30 GE Professional Association meeting.

1 0

N. De Suray (1), J. Salleron (2), G. Vernier-Massouille (3), J.C. Grimaud (4), Y. Bouhnik (5), D. Laharie (6), J.L. Dupas (7), H. Pillant (8), L. Picon (9), M. Veyrac (10), M. Flamant (11), G. Savoye (12), R. Jian (13), M. De Vos (14), E. Piver (15), J.F. Colombel (3), E. Louis (16) / [1] Grand Hôpital De Charleroi, Hôpital Saint-Joseph, Gilly, [2] Centre Hospitalier Régional Universitaire De Lille, France, [3] Hôpital Claude Huriez, Lille, France, [4] Hôpital Nord, Marseille, France, [5] Hôpital Beaujon, Clichy, France, [6] Hôpital Haut-Lévêque, Bordeaux, France, [7] Hôpital Nord, Amiens, France, [8] Hôpital Henri Mondor, Créteil, France, [9] Hôpital Trousseau, Tours, France, [10] Hôpital Saint-Eloi, Montpellier, France, [11] Hôpital Hôtel Dieu, Nantes, France, [12] Hôpital Charles Nicolle, Rouen, France, [13] Hôpital Georges Pompidou, Paris, France, [14] UZ Gent, [15] Université François Rabelais, Tours, France, [16] ULg

F r i d a y

disease after infliximab withdrawal.

09 :45 I14 Invited lecture : “ Colon cancer in IBD: Is the risk still significant today?”

D. Franchimont / ULB Erasme, Brussels

10:15

coffee break

Session two:

• Moderators : E. Louis, M. de Vos 10 :40 I15 Proctectomy with end colostomy is ineffective for patients with anorectal Crohn’s Disease.

A.De Buck Van Overtraeten, A. Wolthuis, S. Vermeire, G. Van Ascche, P. Rutgeerts, F. Penninckx, A. D’hoore / KULeuven

10:45 I16 Single access laparoscopic restorative proctocolectomy: initial experience and feasibility study.

D. Leonard, C. Remue, E. Cotte, I. Stefanescu, H. Vincart, A. Kartheuser / UCL St-Luc

40



41

R OO M «Fabiola & Baudouin»

PLENARY SESSION

Session one:

• Moderators : M. Buset , A. Geerts 14:00 D01 Inhibition of VEGFR2 attenuates steatosis and inflammation in a diet-induced mouse model for NASH.

S. Coulon (1), F. Heindryckx (1), B. Blomme (1), C. Vansteenkiste (1), L. Libbrecht (1), J.M. Stassen (2), B. Jonckx (2), I. Leclercq (3), N. Lanthier (3), H. Vanvlierberghe (1), I. Colle (1), A. Geerts (1) / [1] UZ Gent, [2] ThromboGenics NV., Heverlee, [3] UCL St Luc, Brussels

14:12 D02 Design and validation of scores for the prospective assessment of NASH: a large single-centre study.

S. Francque, A. Verrijken, I. Mertens, C. Van Gils, G. Hubens, E. Van Marck, V. Van Marck, P. Pelckmans, P. Michielsen, L. Van Gaal / UZ Antwerpen

14:24 D03 Anti-reflux surgery after congenital diaphragmatic hernia repair. 1 0

Belgian single-center cohort.

W. Laleman, W. Vansteenbergen, S. Van Der Merwe, C. Verslype, F. Nevens / KULeuven

14:48 D05 Impaired integrity and altered expression of cell-to-cell adhesion proteins in functional dyspepsia.

H. Vanheel (1), C. Martinez (2), T. Vanuytsel (1), N. Pardon (1), M. Vicario (2), J. Soderholm (3), J. Tack (1), R. Farré (1) / [1] KULeuven, [2] Hospital Universitari Vall d’Hebron, Barcelona, Spain, [3] Faculty of Health Sciences, Linköping, Sweden

15:00 D06 A longer Interval between Chemoradiotherapy and TME for Rectal Cancer Improves Response and Outcome.

A. Wolthuis, F. Penninckx, K. Haustermans, G. Dehertogh, S. Fieuws, E. Vancutsem, A. Dhoore / KULeuven

15:12 D07 State of the art lecture: “GWAS for the gastroenterologist: clinical implications”.

S. Vermeire / KULeuven

15:40

coffee break

Session two:

• Moderators : L. van Grunsven, E. Louis 16:00 D08 The occurrence of severe colitis in the graft of intestinal transplantation recipients.

G. Veereman (1), F. Lacaille (2), F. Ruemmele (2), C. Talbotec (2), C. Chardot (2), O. Goulet (2) / [1] UZ Brussel, [2] Hôpital Necker, Paris, France

42


16:12 D09 Genetic and functional evidence for a role of CYLD in Crohn’s Disease.

I. Cleynen (1), E. Vazeille (2), M. Artieda (3), M. Szczypiorska (3), M.A. Bringer (2), H.W. Verspaget (4), P.L. Lakatos (5), F. Seibold (6), K. Parnell (7), R.K. Weersma (8), J. Mahachie John (9), R. Morgan-Walsh (10), D. Staelens (1), I. Arijs (1), S. Müller (6), A. Tordai (11), D. Hommes (4), T. Ahmad (7), C. Wijmenga (8), S. Pender (10), P. Rutgeerts (12), D. Lottaz (6), S. Vermeire (12), A. Darfeuille-Michaud (2) / [1] KULeuven, [2] Université d’Auvergne, Clermont-Ferrand, France, [3] Progenika Biopharma, Derio, Spain, [4] Leiden University Medical Center, Netherlands, [5] Semmelweis University, Budapest, Hungary, [6] University Hospital of Bern, Inselspital, Switzerland, [7] University of Exeter & Plymouth, United Kingdom, [8] University of Groningen, Netherlands, [9] ULg [10] University of Southampton, UK, [11] Hungarian National Blood Transfusion Service, Budapest, Hungary, [12] KULeuven

16:24 D10 Calprotectin as a marker of disease activity in UC patients under infliximab maintenance treatment.

M. De Vos (1), J. Jahnsen (2), J. Vandervoort (3), G. D’haens (4), O. Dewit (5), E. Louis (6), D. Franchimont (7), F. Baert (8), R. Torp (9), P. Potvin (10), P. Van Hootegem (11), M. Henriksen (12), B. Vander Cruyssen (1), S. Vermeire (13) / [1] UZ Gent, [2] Oslo University Hospital, Aker, Norway, [3] OLV Ziekenhuis, Aalst, [4] Imelda Hospital, Bonheiden, [5] UCL St Luc, Brussels, [6] ULg, [7] ULB Erasme Brussels, [8] H. Hart Hospital, Roseselare, [9] Innlandet Hospital, Hamar, Norway, [10] St Jozefkliniek, Bornem, [11] AZ Sint-Lucas, Brugge, [12] Ostfold Fredrikstad Hospital, Norway, [13] KULeuven

16:36 D11 Adult liver progenitor cells differentiate toward mature hepatocytes after cde diet-induced injury.

R. Español Suñer, R. Carpentier, N. Van Hul, F. Lemaigre, I. Leclercq /UCL St Luc, Brussels

1 0

F RIDAY

14:36 D04 Peroral cholangioscopy in biliopancreatic interventions : results of

PLENARY SESSION

F r i d a y

T. Verbelen, W. Coosemans, P. Deleyn, P. Nafteux, D. Vanraemdonck, I. Hoffman, J. Deprest, T. Lerut, H. Decaluwe / KULeuven


16 :48 D12 Efficacy and safety issues of radiofrequency ablation in long Barrett’s esophagus.

J. Carausu, A. Mourin, H. Piessevaux, P. Deprez / UCL St Luc, Brussels

17 :00 D13 Association of protective IL13 polymorphism with irritable bowel syndrome.

M.M. Wouters (1), D. Lambrechts (2), I. Cleynen (1), P. Whorwell (3), K. Lambaerts (1), L. Agréus (4), A. Dlugosz (4), P. Thelin-Schmidt (4), J. Halfvarson (5), M. Simren (6), B. Ohlsson (7), P. Karling (8), S. Van Wanrooy (1), S. Vermeire (1), G. Lindberg (4), R. Spiller (9), M. D’amato (4), G. Boeckxstaens (1) / [1] KULeuven, [2] VIB, Leuven, [3] University of Manchester, United Kingdom, [4] Karolinska University Hospital, Stockholm, Sweden, [5] Örebro University Hospital, Sweden, [6] Sahlgrenska Hospital, Göteborg, Sweden, [7] Lund University, Malmö, Sweden, [8] Umeå University, Sweden, [9] University of Nottingham, UK

17 :12 D14 GLEM/LOK report on chronic pancreatitis management in Belgium. Results of a national survey.

M. Delhaye (1), W. Van Steenbergen (2), M. Arvanitakis (1), J. Deviere (1), P. Deprez (3), R. Fiasse (3), C. De Galocsy (4) / [1] ULB Erasme, Brussels, [2] KULeuven, [3] UCL St Luc, Brussels, [4] CH Joseph Bracops, Brussels


43

R OO M «Lo bby area»

POSTER SESSION 10H15 - 11H00 15h40 - 16h00

• Reviewers : E. Macken, H. Louis

R OO M «Lo bby area» P26

A rare case of protein-loosing enteropathy and congenital lymphedema?

S. Vande Velde (1), S. Van Biervliet (1), M. Van Winckel (1), R. De Bruyne (1), B. Callewaert (1), O. Vanacker (1), J. Degraeuwe (2) / [1] UZ Gent [2] AZ Maria Middelares, Gent

E14

P27

Eosinophilic enteritis: more questions than answers. Early experience with Single Incision Laparoscopic Surgery (SILS) for the placement of a gastrostomy. K. De Vogelaere, K. Vanderlinden, N. Vandewinkel, G. Delvaux / UZ Brussel

E17

Is Hirschprung disease diagnosed in children older than 1 year of age with constipation ?

M. Aerts (1), F. Mana (1), B. Neyns (1), D. De Looze (2), C. Reenaers (3), D. Urbain (1) / [1] UZ Brussel, [2] UZ Gent, [3] ULg

P29

Early experience with Single-Port Laparoscopic Nissen fundoplication in children. K. De Vogelaere, K. Vanderlinden, A. De Backer, G. Delvaux / UZ Brussel

E19

Gastro-oesophageal reflux and gastric emptying in children with cystic fibrosis.

P30

POSTERS BGDO Cisplatin-modified de gramont in second line therapy for pancreatic adenocarcinoma.

P31

Ambulatory administration of DCF chemotherapy in gastric and gastroesphageal cancers – Community Hospital experience.

P32

M. Criel, K. Bulte, F. Geurs, I. Hilderson, J. Ponette / Sint Maria Ziekenhuis, Halle

44


Natural history and prognostic factors of patients with high risk pT4 stage II colon Cancer.

B. Vos (1), R. Marechal (1), P. Demetter (1), L. Verset (1), M. Fernandez (2), A. Hendlisz (2), J.L. Van Laethem (1) / [1] ULB Erasme, Brussels, [2] ULB Bordet, Brussels

V. Ky (1), M. Hav (1), E. Monsaert (2), E. Vanderstraeten (2), D.B. Katrien (2), N. Van Damme (1), S. Laurent (1), K. Geboes (1) / [1] UZGent, [2] Maria Middelares Ziekenhuis, Gent

P25

Cytoreductive surgery and Hyperthermic intraperitoneal chemotherapy for colorectal Carcinomatosis.

E. Cotte (1), S. Van Den Broeck (2), C. Remue (1), D. Leonard (1), F. Lois (1), P. Forget (1), M. De Kock (1), P.F. Laterre (1), X. Wittebole (1), Y. Humblet (1), M. Van Den Eynde (1), E. Danse (1), C. Dragean (1), C. Sempoux (1), A. Jouret-Mourin (1), B. Crispin (1), G. Leclercq (1), L. Delcarte (1), J. Jamart (3), A. Kartheuser (1) / [1] UCL St Luc, Brussels,[2] UZ Antwerpen, [3] UCL, Mont-Godinne

B. Hauser, A. Malfroot, E. De Wachter, I. De Schutter, T. Devreker, G. Veereman, E. De Greef, Y. Vandenplas / UZ Brussel

P24

Primary small bowel adenocarcinoma: retrospective analysis of 29 cases in the Antwerp region. T. Moreels (1), T. Botelberge (2), J. Callens (3), B. De Schepper (2), J. Holvoet (4), J. Maus (3), B. Naessens (5), I. Ruytjens (4), D. Sprengers (2), P.H. Steger (6), L. Terriere (4), L. Verbist (7), H. Büscher (8) / [1] UZ Antwerpen, [2] Sint Augustinus Ziekenhuis, Antwerpen, [3] KLINA, Brasschaat, [4] ZNA Middelheim, Antwerpen, [5] AZ Nikolaas, Sint-Niklaas, [6] SintVincentiusziekenhuis, Antwerpen, [7] ZNA Jan Palfijn, Merksem, [8] AZ St Jozef, Malle

B. Hauser, T. Devreker, G. Veereman, E. De Greef, Y. Vandenplas / UZ Brussel

E18

Small bowel metastases from melanoma: does videocapsule provide additional information after PET-CT?

1 0

F RIDAY

E16

P28

Laparoscopic resection of gastric GIST is safe and effective, irrespective of size. K. De Vogelaere, A. Hoorens, I. Van Loo, G. Delvaux / UZ Brussel


F r i d a y

1 0

L. Dekeyzer, S. Vande Velde, S. Van Biervliet, R. De Bruyne, M. Van Winckel / UZ Gent

Long-acting octreotide as secondary prevention of chemotherapyinduced diarrhea.

A.Hendlisz (1), M. Van Den Eynde (2), G. Machiels (1), I. Dero (3), K. Geboes (3), M. De Man (4), K. Hendrickx (4), T. Delaunoit (5), E. Monsaert (6), E. Vanderstraeten (6), J.L. Van Laethem (7), W. Lybaert (8), S. Holbrechts (9), K. Wouters (10), M. Peeters (10) / [1] ULB Bordet, Brussels, [2] UCL St Luc, Brussels, [3] UZ Gent, [4] OLV Ziekenhuis, Aalst, [5] Hôpital de Jolimont, Haine-Saint-Paul, [6] Maria Middelares Ziekenhuis, Gent, [7] ULB Erasme, Brussels, [8] AZ Nikolaas, Sint-Niklaas, [9] CHU Ambroise Paré, Mons, [10] UZ Antwerpen

Developing a modified quality of life questionnaire for children with spina bifida. J. Daelman, J. Laridaen, R. De Bruyne, S. Van Biervliet, S. Vande Velde, M. Van Winckel / UZ Gent

E15

CRS+HIPC to treat peritoneal carcinomatosis from upper GI cancer; 1-y analysis of the HIPCUpp-trial.

B. Topal, F. Huysentruyt, A. Van Den Broeck, G. Sergeant, R. Aerts, C. Verslype, E. Van Cutsem, W. Laleman, S. Tejpar, W. Van Steenbergen, V. Vandecaveye, T. Roskams, H. Prenen / KULeuven

POSTERS PEDIATRY - BeSPGHAN

E13


45

R OO M «Lo bby area»


  



POSTERS BSGIE

G11

Screening of Proximal Colon Adenomas: Conventional Colonoscopy Versus Chromoendoscopy. S. Mouzyka / Hospital Lissod, Kiev, Ukraine

G12

Heterogeneity of Scoring Systems in ODS Assessment after STARR: a Report from a Systematic Review.

A. D’hoore (1), A. Stuto (2), B. Van Geluwe (1), F. Da Pozzo (2), S. Fieuws (1), P.A. Lehur (3) / [1] KULeuven, [2] Ospedaliera Santa Maria Degli Angeli, Sarone, Italy, [3] Hôpital Hôtel Dieu, Nantes, France

G13

Cholangioscopy in a patient with Roux-en-Y limb via a gastric access loop.

    

G. Mavrogenis, Y. Hoebeke, P. Warzee / Notre Dame, Charleroi

F RIDAY

1 0

POSTERS IBD BIRD

I20

Pouchitis has a similar mucosal gene expression profile as active ileal Crohn’s disease.

I.Arijs, J. Van Der Goten, M. Ferrante, K. Machiels, V. De Preter, L. Van Lommel, G. Van Assche, S. Vermeire, F. Schuit, P. Rutgeerts / KULeuven

I21

Gene expression differences between early and post-operative recurrent/late ileal Crohn’s disease.

  



J. Van Der Goten, I. Arijs, G. De Hertogh, M. Ferrante, K. Machiels, L. Van Lommel, G. Van Assche, S. Vermeire, F. Schuit, P. Rutgeerts / KULeuven

I22

Mucosal expression of CarcinoEmbryonic Antigen-related Cell Adhesion Molecule 6 (CEACAM6) in IBD.

D. Staelens, I. Arijs, J. Van Der Goten, L. Van Lommel, G. Van Assche, S. Vermeire, F. Schuit, G. De Hertogh , P. Rutgeerts / KULeuven

I23

Differentially expressed microRNAs in inflamed colon of patients with ulcerative Colitis. J. Van Der Goten, I. Arijs, L. Van Lommel, W. Vanhove, V. De Preter, P. Rutgeerts, F. Schuit, S. Vermeire / KULeuven

I24 Butyricicoccus pullicaecorum prevents inflammation in the TNBSinduced colitis rat Model.

V. Eeckhaut, S. Maes, M. Steppe, R. Ducatelle, F. Van Immerseel / UZGent

POSTERS NUTRITION

N13 Comparison of two extensively hydrolyzed formulas for the treatment of children with cow’s milk protein allergy. Y. Vandenplas (1), Altherastudygroup (2) / [1] UZ Brussel

N14 Specific hunger- and satiety-mediated tuning of guinea pig enteric nerve activity.

L. Roosen, W. Boesmans, M. Dondeyne, I. Depoortere, J. Tack, P. Vanden Berghe / KULeuven 46




Friday Night Party On Friday February 10, 2012 at 8:00pm

F RIDAY

1 0

MSD Venue : Koninklijke Gaanderijen Albert I-Promenade 75 8400 Oostende

8.00 pm : Aperitive 8.45 pm : Dinner

your partner in Gastroenterology

The Belgian Week Steering Committee is looking forward to welcoming all the registrered participants and partners to the Friday Night Party ! The aperitive will be followed by a very nice dinner and music to make it a splendid evening and night! Make sure to join us and register on the website : www.belgianweek.be or www.bwge.be 31-Dec-2012 REM-2010-BE-3073-J

48


SEV E N SOC I ET I ES P OSTGRAD UATE CO U RSE


“Management of complications of cirrhosis.”

• Moderators : V. Donckier, M. Peeters, L. Libbrecht 09:00 S01 Invited lecture : “Prognostic factors in liver biopsy for HCC.” J. Zucman-Rossi / Paris, France

09:25 S02 Invited lecture : “Staging and local treatment of HCC.” B. Op de Beeck / UZAntwerpen

09:50 S03 Invited lecture : “Indications for transplantations and management of HCC while on waiting list”.

J..F. Dufour /Bern, Switzerland

Session three:

• Moderators : Z. Hassoun, F. Nevens , N. Bourgeois 14:30 S10 Invited lecture : “Ascites and hyponatremia.” S. Francque / UZ Antwerpen

14:50 S11 Invited lecture : “Renal dysfunction in cirrhosis.” M. Wissing / UZ Brussel

15:10 S12 Invited lecture : “Spontaneous bacterial peritonitis and other infections.”

10:15 S04 Invited lecture : “Medical treatment of advanced HCC.” C. Verslype / KULeuven

10:40

14:15 S09 BROHEE LECTURE : “Update in treatment of achalasia.” G. Boeckxstaens / KULeuven

Session one:


SEVE N SOC I ETI ES POSTGRAD UATE CO U RSE

T. Gustot / ULB Erasme, Brussels

15:30 S13 Invited lecture : “Hepatopulmonary syndrome and portopulmonary hypertension.”

coffee break

H. Van Vlierberghe / UZGent

15:50 S14 Invited lecture : “Coagulation disorders in cirrhosis (hypo and

Session two:

• Moderators : W. Laleman, O. Detry, L. Defreyne 11:00 S05 Invited lecture : “Pathophysiology of portal hypertension.” H. Reynaert / UZ Brussel

hyper).”

J. Schouten / Rotterdam, Netherlands

16:10 S15 Invited lecture :“Indications for liver transplantation in end stage liver disease.”

J. Delwaide / ULg

11:20 S06 Invited lecture : “Management of acute variceal bleeding and GAVE.” O. Le Moine / ULB Erasme, Brussels

11:40 S07 Invited lecture : “Primary and Secondary prophylaxis of variceal bleeding.”

P. Stärkel / UCL St Luc, Brussels

X. Stéphenne / UCL St Luc, Brussels

12 :20

BWG 2012 AWARDS :

IBD – BIRD

BWG 2012: Best Oral Presentation of

BGDO

Pediatry - BeSPGHAN

12:30

LUNCH

the Plenary Session Best Poster

1 1

SA T URDAY

due to portal Hypertension.”

S a t u r d a y

1 1

12:00 S08 Invited lecture : “Management of children with GI haemorrhage

50



51

T h u r s d a y 9

T h u r s d a y

9

Access to the Congress Venue

1 0

Koningin Astridlaan 7, B-8400 Oostende Tel : +32 59 80 66 44 / Fax : +32 59 80 52 74 Website : www.thermaepalace.be

Thermae Palace is easy accessible : via E40 - A10, Brussels (114 km), Ghent (70 km), Bruges (29 km) via E40 – A10, Ghent (70 km), Bruges (29 km) via E40 – A18, Veurne (33 km), Nieuwport (21 km) via A17 – A10, Courtrai (62 km), Bruges (29 km) via E17–E40–A10, Antwerp (123 km), Ghent (70 km), Bruges (29 km)

Entering Ostend, at the Kennedy-roundabout follow the direction Middelkerke/Nieuwpoort, third exit. Follow the Elisabethlaan + Northlaan until last traffic lights before the tram tracks. Then turn right and follow the Troonstraat, changes to Koningin Astridlaan, till you see the hotel on your left hand side.

S a t u r d a y

1 1

1 0

F RIDAY

Thermae Palace Oostende

from Aachen from Brussels from Dunkerque from Lille from Breda

Parking will be available : - At the Thermae Palace - Across the street at the Race-track Participants will be responsible for the cost of parking.

1 1

SA T URDAY

F r i d a y

Address :

52



53

What is Yakult? Yakult is a fermented milk drink containing Lactobacillus casei Shirota (LcS), a unique probiotic strain discovered in 1930 and backed by over 80 years of research and development. Yakult was launched in Belgium in 1995 and was one of the first probiotic products in Europe. As a company Yakult remains at the forefront of education and research into probiotics and is committed to supporting healthcare professionals and increasing their understanding of the potential benefits of probiotics. Extensive research has been conducted on LcS and Yakult, with scientific publications dating back to the 1950s. Human studies have shown that LcS reaches the intestines alive and helps to maintain a healthy balance of the intestinal microbiota. A body of scientific evidence, including numerous human trials, has demonstrated positive health benefits associated with daily consumption of LcS and Yakult. These data are relevant to healthy people, and those with sub-optimal health and certain conditions.

edition

I want to receive the full study of:

❍ ❍

❍

Fermented milk containing Lactobacillus casei strain Shirota reduces incidence of hard or lumpy stools in healthy population (T. Sakai et al. International Journal of food sciences and Nutrition, June 2011; 62 (4): 423-430) Daily Probiotic’s (Lactobacillus casei Shirota) Reduction of Infection Incidence in Athletes (Michael Gleeson et al. International journal of Sport Nutrition and Exercise Metabolism, 21, 2011; 55-64).

By Email :

Title:

XXV

th

February 28 to March 2, 2013

............................................................................................................................

First Name: Address: Postcode: Country:

....................................................................................................................

.......................................................................................................................

.................................

Town or City:

........................................

............................................................................................

www.yakult.be

A special edition to come…

Partners 2012 P r em i u m P AR T N E RS

M a jo r P AR T N E R

www.astrazeneca.be

Reg u l a r P AR T N E RS ABBOTT PRODUCTS (Solvay)

IPSEN

ACERTYS

JANSSEN CILAG

ACTIAL FARMACEUTICA

MEDICAL DEVICE SERVICES

ALERE

MEDVISION BENELUX

BENETEC

MENARINI

BIOCODEX

MERCK

BMS

NORGINE

BOUCART Medical

NOVARTIS

CHIESI

OLYMPUS

CAMPRO SCIENTIFIC

PENTAX - HITACHI

COOK Medical

De Beukelaer Medical

DANONE

PFIZER

Dr FALK PHARMA BENELUX

RMS Endoscopy

ECCE

SHIRE

ECHOSENS

SIRTEX

ENDO PROJECTS

THERASPHERE - MDS NORDION

ERBE

TRAMEDICO

EUMEDICA

VESALE PHARMA

FERRING

WILL PHARMA

FIDES MEDICAL

YAKULT

FUJINON - Onis

Z-PROJECTS

Belgian Week of Gastroenterology

Recommend Documents